Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity
In conjugate, inactivated, recombinant, and toxoid vaccines, adjuvants are extensively and essentially used for enhanced and long-lasting protective immune responses. Depending on the type of diseases and immune responses required, adjuvants with different design strategies are developed. With alumi...
Saved in:
| Published in | Vaccine Vol. 37; no. 24; pp. 3167 - 3178 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier Ltd
27.05.2019
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | In conjugate, inactivated, recombinant, and toxoid vaccines, adjuvants are extensively and essentially used for enhanced and long-lasting protective immune responses. Depending on the type of diseases and immune responses required, adjuvants with different design strategies are developed. With aluminum salt-based adjuvants as the most used ones in commercial vaccines, other limited adjuvants, e.g., AS01, AS03, AS04, CpG ODN, and MF59, are used in FDA-approved vaccines for human use. In this paper, we review the uses of different adjuvants in vaccines including the ones used in FDA-approved vaccines and vaccines under clinical investigations. We discuss how adjuvants with different formulations could affect the magnitude and quality of adaptive immune response for optimized protection against specific pathogens. We emphasize the molecular mechanisms of various adjuvants, with the aim to establish structure-activity relationships (SARs) for designing more effective and safer adjuvants for both preventative and therapeutic vaccines. |
|---|---|
| AbstractList | In conjugate, inactivated, recombinant, and toxoid vaccines, adjuvants are extensively and essentially used for enhanced and long-lasting protective immune responses. Depending on the type of diseases and immune responses required, adjuvants with different design strategies are developed. With aluminum salt-based adjuvants as the most used ones in commercial vaccines, other limited adjuvants, e.g., AS01, AS03, AS04, CpG ODN, and MF59, are used in FDA-approved vaccines for human use. In this paper, we review the uses of different adjuvants in vaccines including the ones used in FDA-approved vaccines and vaccines under clinical investigations. We discuss how adjuvants with different formulations could affect the magnitude and quality of adaptive immune response for optimized protection against specific pathogens. We emphasize the molecular mechanisms of various adjuvants, with the aim to establish structure-activity relationships (SARs) for designing more effective and safer adjuvants for both preventative and therapeutic vaccines. |
| Author | Sun, Bingbing Liang, Zhihui Shi, Shuting Zhu, Haoru Xia, Xinyu Ma, Xuehu |
| Author_xml | – sequence: 1 givenname: Shuting surname: Shi fullname: Shi, Shuting organization: State Key Laboratory of Fine Chemicals, Dalian University of Technology, 2 Linggong Road, 116024 Dalian, China – sequence: 2 givenname: Haoru surname: Zhu fullname: Zhu, Haoru organization: State Key Laboratory of Fine Chemicals, Dalian University of Technology, 2 Linggong Road, 116024 Dalian, China – sequence: 3 givenname: Xinyu surname: Xia fullname: Xia, Xinyu organization: State Key Laboratory of Fine Chemicals, Dalian University of Technology, 2 Linggong Road, 116024 Dalian, China – sequence: 4 givenname: Zhihui surname: Liang fullname: Liang, Zhihui organization: State Key Laboratory of Fine Chemicals, Dalian University of Technology, 2 Linggong Road, 116024 Dalian, China – sequence: 5 givenname: Xuehu surname: Ma fullname: Ma, Xuehu organization: State Key Laboratory of Fine Chemicals, Dalian University of Technology, 2 Linggong Road, 116024 Dalian, China – sequence: 6 givenname: Bingbing orcidid: 0000-0002-5444-5078 surname: Sun fullname: Sun, Bingbing email: bingbingsun@dlut.edu.cn organization: State Key Laboratory of Fine Chemicals, Dalian University of Technology, 2 Linggong Road, 116024 Dalian, China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31047671$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkD1P5DAURS3ECmbY_QmgSDQ0CX6OPYlpEEJ8SbPaZlltZzn2CziaOGA7I_HvyWgGChqq15x779OZk30_eCTkGGgBFBbnXbHWxjiPBaMgC8oLKsQemUFdlTkTUO-TGWULnnOg_w_JPMaOUipKkAfksATKq0UFM_L737Yl07Yb19qneJE9eoshJu2t809ZesYspjCaNIYJ8zbr0Txr72KfDe1nzhmX3n6SH61eRfy1u0fk8fbm7_V9vvxz93B9tcxNKcuUY91ywRCgAhTI66aUteQamZTQ1K2kVlphoKXW6kbauoKKgpZNaxqjEVl5RM62vS9heB0xJtW7aHC10h6HMSrGmGSl4AATevoF7YYx-Om7DcWEFAtWTZTYUiYMMQZs1UtwvQ5vCqja-Fad2vlWG9-KcjX5nnInu_ax6dF-pj4ET8DlFsBJx9phUNE49AatC2iSsoP7ZuIdLQSWKw |
| CitedBy_id | crossref_primary_10_1080_14787210_2023_2182771 crossref_primary_10_3389_fimmu_2020_579907 crossref_primary_10_15252_embr_202152447 crossref_primary_10_3390_pharmaceutics13040501 crossref_primary_10_3389_fimmu_2021_684823 crossref_primary_10_3390_pathogens12060787 crossref_primary_10_2174_1568009622666220214103533 crossref_primary_10_1080_21645515_2024_2317439 crossref_primary_10_3389_fimmu_2022_1079047 crossref_primary_10_1051_e3sconf_202341601008 crossref_primary_10_1088_1361_6528_ad1644 crossref_primary_10_3390_polym13234097 crossref_primary_10_3390_vaccines9050499 crossref_primary_10_3389_fimmu_2020_589833 crossref_primary_10_1016_j_exppara_2022_108427 crossref_primary_10_4155_tde_2021_0006 crossref_primary_10_1007_s40618_021_01707_0 crossref_primary_10_1007_s12020_021_02919_3 crossref_primary_10_3390_vaccines9121408 crossref_primary_10_1007_s40121_023_00896_w crossref_primary_10_1016_j_carres_2023_108875 crossref_primary_10_5937_arhfarm1906420K crossref_primary_10_1021_acsbiomaterials_9b01255 crossref_primary_10_15789_1563_0625_DOA_2824 crossref_primary_10_1016_j_intimp_2023_109882 crossref_primary_10_1016_j_jconrel_2023_11_047 crossref_primary_10_3390_toxins16010033 crossref_primary_10_2139_ssrn_4047253 crossref_primary_10_1016_j_fsi_2022_07_027 crossref_primary_10_1080_10837450_2024_2305107 crossref_primary_10_1016_j_jconrel_2020_04_001 crossref_primary_10_1021_acs_jmedchem_3c02385 crossref_primary_10_1111_tid_14051 crossref_primary_10_1016_j_xphs_2023_10_009 crossref_primary_10_3390_v15020347 crossref_primary_10_1038_s41541_022_00495_9 crossref_primary_10_3390_vaccines11101572 crossref_primary_10_3390_vaccines11050902 crossref_primary_10_1016_j_actbio_2024_05_050 crossref_primary_10_1080_09540105_2021_1970722 crossref_primary_10_1016_j_vetimm_2022_110484 crossref_primary_10_4103_bbrj_bbrj_18_24 crossref_primary_10_3390_vaccines9040359 crossref_primary_10_1039_D1MD00372K crossref_primary_10_1080_21645515_2023_2186110 crossref_primary_10_1128_msystems_00927_22 crossref_primary_10_1172_JCI146956 crossref_primary_10_1002_adhm_202300085 crossref_primary_10_1002_btm2_10188 crossref_primary_10_1186_s12967_024_05160_4 crossref_primary_10_12688_f1000research_145766_1 crossref_primary_10_3389_fimmu_2020_613496 crossref_primary_10_1007_s10989_024_10617_7 crossref_primary_10_1093_cei_uxad033 crossref_primary_10_1002_adfm_202112273 crossref_primary_10_3390_ijms241512054 crossref_primary_10_3390_pharmaceutics13030390 crossref_primary_10_1002_advs_202000771 crossref_primary_10_3390_vaccines12010060 crossref_primary_10_3390_v15051198 crossref_primary_10_1016_j_ijbiomac_2023_126440 crossref_primary_10_1007_s00044_024_03227_x crossref_primary_10_1016_j_phrs_2022_106195 crossref_primary_10_3390_medicina59020364 crossref_primary_10_3390_vaccines11050914 crossref_primary_10_1364_BOE_527912 crossref_primary_10_3390_vaccines12010038 crossref_primary_10_3390_vaccines9091039 crossref_primary_10_1016_j_addr_2021_113899 crossref_primary_10_1080_21645515_2022_2062982 crossref_primary_10_3390_vaccines11071172 crossref_primary_10_3390_vaccines11081304 crossref_primary_10_1007_s10787_023_01391_x crossref_primary_10_1007_s12275_024_00119_y crossref_primary_10_1016_j_nano_2024_102749 crossref_primary_10_3390_vaccines12020191 crossref_primary_10_1166_jbn_2020_3007 crossref_primary_10_1007_s40521_022_00311_8 crossref_primary_10_3390_pathogens11121444 crossref_primary_10_1021_acsinfecdis_2c00362 crossref_primary_10_3389_fimmu_2023_1156714 crossref_primary_10_1016_j_carbpol_2021_118139 crossref_primary_10_1186_s12879_024_09262_8 crossref_primary_10_1007_s10719_023_10142_7 crossref_primary_10_1016_j_heliyon_2023_e18039 crossref_primary_10_3390_vaccines10050819 crossref_primary_10_1002_anie_202312624 crossref_primary_10_12677_NAT_2024_141001 crossref_primary_10_3390_biom11111617 crossref_primary_10_1016_j_actbio_2022_12_042 crossref_primary_10_3389_fimmu_2021_701445 crossref_primary_10_1111_cod_14180 crossref_primary_10_3390_biom13071085 crossref_primary_10_1016_S0140_6736_21_00241_5 crossref_primary_10_1016_j_regg_2019_09_001 crossref_primary_10_1021_acsnano_4c02685 crossref_primary_10_1210_clinem_dgac550 crossref_primary_10_1016_j_aquaculture_2023_739634 crossref_primary_10_1016_j_isci_2022_104456 crossref_primary_10_1016_j_jconrel_2024_03_045 crossref_primary_10_1016_j_jcis_2022_07_022 crossref_primary_10_1016_j_molimm_2021_05_003 crossref_primary_10_1016_j_biologicals_2022_10_001 crossref_primary_10_1016_j_vaccine_2020_09_081 crossref_primary_10_1021_acs_molpharmaceut_2c00489 crossref_primary_10_30895_2221_996X_2020_20_4_245_256 crossref_primary_10_1016_j_bjid_2021_101606 crossref_primary_10_1038_s41392_023_01557_7 crossref_primary_10_3390_vaccines9030222 crossref_primary_10_1002_JLB_5A0521_242R crossref_primary_10_1016_j_jff_2023_105781 crossref_primary_10_1039_D2CS00848C crossref_primary_10_1051_bioconf_20248601020 crossref_primary_10_1371_journal_pone_0254628 crossref_primary_10_3390_pharmaceutics16070891 crossref_primary_10_1016_j_vaccine_2024_05_024 crossref_primary_10_3390_vaccines9111278 crossref_primary_10_1016_j_biomaterials_2021_120960 crossref_primary_10_1016_j_colsurfa_2020_125564 crossref_primary_10_3389_fimmu_2022_1075662 crossref_primary_10_3390_nano10050823 crossref_primary_10_1016_j_bsheal_2022_03_002 crossref_primary_10_3390_vaccines12010021 crossref_primary_10_1021_acsami_1c17804 crossref_primary_10_1016_j_biopha_2024_116510 crossref_primary_10_1016_j_ejpb_2022_11_023 crossref_primary_10_1016_j_ijpharm_2024_123802 crossref_primary_10_1016_j_vaccine_2020_03_020 crossref_primary_10_1016_j_antiviral_2024_105941 crossref_primary_10_3390_v14071553 crossref_primary_10_1021_acs_biomac_1c01052 crossref_primary_10_1016_j_intimp_2021_108298 crossref_primary_10_1016_j_sjbs_2022_103337 crossref_primary_10_1038_s41598_021_90318_z crossref_primary_10_3390_pharmaceutics14020423 crossref_primary_10_1021_acs_jmedchem_3c01248 crossref_primary_10_1080_22221751_2022_2050951 crossref_primary_10_3390_vaccines8040754 crossref_primary_10_1016_j_vaccine_2024_07_016 crossref_primary_10_1080_14760584_2023_2238807 crossref_primary_10_3390_ijms25031707 crossref_primary_10_4049_jimmunol_2300038 crossref_primary_10_1016_j_vaccine_2020_07_018 crossref_primary_10_3390_biom13071053 crossref_primary_10_1002_adfm_202111670 crossref_primary_10_1111_tbed_13772 crossref_primary_10_3389_fimmu_2023_1187773 crossref_primary_10_1021_acsbiomaterials_3c01154 crossref_primary_10_1016_j_biomaterials_2024_122569 crossref_primary_10_3390_ijms23010031 crossref_primary_10_3390_vaccines9060563 crossref_primary_10_1080_21645515_2023_2264594 crossref_primary_10_1021_acsmedchemlett_3c00301 crossref_primary_10_1002_ppap_202000051 crossref_primary_10_1039_D1BM01333E crossref_primary_10_17827_aktd_975632 crossref_primary_10_1016_j_jics_2023_101008 crossref_primary_10_1111_imm_13526 crossref_primary_10_1016_j_etap_2020_103404 crossref_primary_10_1016_j_intimp_2024_111817 crossref_primary_10_3389_fendo_2022_938001 crossref_primary_10_3389_fvets_2022_857183 crossref_primary_10_3390_cells10113048 crossref_primary_10_1080_00439339_2022_2091502 crossref_primary_10_1186_s13578_024_01207_7 crossref_primary_10_3390_pharmaceutics12100989 crossref_primary_10_1021_acsami_0c10276 crossref_primary_10_1002_ange_202312624 crossref_primary_10_1016_j_toxicon_2022_05_045 crossref_primary_10_3389_fimmu_2020_01673 crossref_primary_10_1097_MOP_0000000000000868 crossref_primary_10_1016_j_vaccine_2020_01_051 crossref_primary_10_1016_j_ijbiomac_2021_10_005 crossref_primary_10_1021_acs_jmedchem_0c01627 crossref_primary_10_3390_ph17020201 crossref_primary_10_1007_s11684_023_1034_6 crossref_primary_10_1002_anie_202301059 crossref_primary_10_3390_pharmaceutics15020348 crossref_primary_10_1093_femspd_ftab057 crossref_primary_10_3389_fimmu_2022_1088130 crossref_primary_10_1038_s41577_023_00937_y crossref_primary_10_3390_vaccines10091383 crossref_primary_10_1021_acsomega_3c02030 crossref_primary_10_31466_kfbd_1138819 crossref_primary_10_3390_nano11061508 crossref_primary_10_1007_s11095_024_03665_7 crossref_primary_10_1007_s13346_021_00968_9 crossref_primary_10_2174_0929866528666211125110701 crossref_primary_10_3389_fphar_2023_1103940 crossref_primary_10_1002_ange_202301059 crossref_primary_10_1002_smll_202305567 crossref_primary_10_1038_s41598_020_77077_z crossref_primary_10_14202_vetworld_2023_68_75 crossref_primary_10_1016_j_drudis_2021_03_007 crossref_primary_10_1016_j_tube_2019_101890 crossref_primary_10_3390_cells9122560 crossref_primary_10_1111_sji_13177 crossref_primary_10_1002_smll_202401631 crossref_primary_10_1111_all_14840 crossref_primary_10_3390_vaccines10071120 crossref_primary_10_1016_j_hlife_2023_12_005 crossref_primary_10_1002_adfm_202201952 crossref_primary_10_1021_acsnano_2c01283 crossref_primary_10_1080_14760584_2021_1941895 crossref_primary_10_3389_fimmu_2021_711650 crossref_primary_10_3390_vaccines8030519 crossref_primary_10_1016_j_jinorgbio_2021_111454 crossref_primary_10_3390_cells10010078 crossref_primary_10_1016_j_matpr_2024_04_006 crossref_primary_10_1124_jpet_123_002031 crossref_primary_10_1134_S0006297924030155 crossref_primary_10_3389_fimmu_2020_00717 crossref_primary_10_1016_j_taap_2022_116358 crossref_primary_10_1016_j_ebiom_2023_104924 crossref_primary_10_1080_17425247_2020_1776259 crossref_primary_10_1111_nyas_14235 crossref_primary_10_1016_j_ijpharm_2023_123568 crossref_primary_10_3390_ijms24054409 crossref_primary_10_1126_sciadv_adi4753 crossref_primary_10_1016_j_vaccine_2024_03_033 crossref_primary_10_1128_spectrum_02564_22 crossref_primary_10_1039_D0BM01518K crossref_primary_10_1002_advs_202300116 crossref_primary_10_3389_fimmu_2022_938598 crossref_primary_10_1016_j_bioadv_2022_212726 crossref_primary_10_1093_glycob_cwaa099 crossref_primary_10_1080_07391102_2020_1869092 crossref_primary_10_1021_acs_jmedchem_0c01660 crossref_primary_10_1016_j_ijpharm_2021_121378 crossref_primary_10_1021_acs_chemrev_3c00409 crossref_primary_10_1021_acs_jmedchem_2c01087 crossref_primary_10_1016_j_addr_2021_113954 crossref_primary_10_1080_14760584_2023_2227699 crossref_primary_10_2478_am_2022_022 crossref_primary_10_3390_pharmaceutics14122557 crossref_primary_10_1016_j_xphs_2021_10_037 crossref_primary_10_1016_j_vaccine_2023_03_067 crossref_primary_10_1016_j_nantod_2022_101445 crossref_primary_10_1016_j_biomaterials_2022_121733 crossref_primary_10_1021_acsinfecdis_3c00159 crossref_primary_10_3390_v13122340 crossref_primary_10_1016_j_ijbiomac_2022_01_169 crossref_primary_10_1016_j_vaccine_2019_11_036 crossref_primary_10_1002_mabi_202200520 crossref_primary_10_1016_j_isci_2024_110189 crossref_primary_10_3390_molecules26020430 crossref_primary_10_1021_acsnano_3c00644 crossref_primary_10_3390_vaccines8010134 crossref_primary_10_1016_j_jconrel_2024_06_054 crossref_primary_10_1080_21645515_2019_1675457 crossref_primary_10_3390_vaccines9101074 crossref_primary_10_1016_j_vaccine_2023_01_005 crossref_primary_10_1016_j_jconrel_2023_04_036 crossref_primary_10_1248_yakushi_19_00174 crossref_primary_10_30895_2221_996X_2021_21_1_20_30 crossref_primary_10_1007_s11814_023_1388_0 crossref_primary_10_1016_j_molimm_2022_05_007 crossref_primary_10_1111_sji_12867 crossref_primary_10_1039_D3TB02861E |
| Cites_doi | 10.1038/2081295a0 10.1128/IAI.00977-07 10.1016/j.vaccine.2014.06.065 10.1016/j.cytogfr.2010.09.003 10.1016/j.vaccine.2017.09.027 10.1586/erv.11.192 10.1016/j.vaccine.2016.05.071 10.1016/j.vaccine.2007.03.045 10.1016/j.vaccine.2017.10.097 10.4161/hv.3.4.4309 10.3181/00379727-156-39951 10.1200/JCO.2001.19.18.3836 10.1021/nn404211j 10.1016/S0169-409X(98)00008-8 10.1016/S0264-410X(02)00169-X 10.1016/j.vaccine.2011.01.011 10.1038/nm.2306 10.1586/14760584.1.1.111 10.1080/14760584.2016.1213632 10.1371/journal.pone.0185843 10.1016/j.vaccine.2007.12.038 10.1016/j.vaccine.2018.07.040 10.1586/erv.11.15 10.1080/21645515.2015.1071455 10.4049/jimmunol.180.8.5402 10.3389/fimmu.2015.00207 10.1089/107999099313893 10.1038/374546a0 10.1586/14760584.6.5.723 10.1016/j.vaccine.2006.08.013 10.1186/1743-422X-8-7 10.1038/nri1329 10.1371/journal.pone.0029231 10.1155/2010/690438 10.1016/j.vaccine.2011.09.061 10.1097/01.aids.0000183514.37513.d2 10.1016/0264-410X(95)00011-O 10.1038/s41541-017-0043-3 10.1002/eji.200838549 10.1586/14760584.2.2.189 10.5582/ddt.2015.01025 10.1038/210747a0 10.1038/252252a0 10.1136/bmj.2.3632.244 10.3389/fimmu.2018.00641 10.1111/j.1600-065X.2008.00723.x 10.1371/journal.pntd.0004423 10.1016/S0167-5699(99)01547-9 10.1016/S1473-3099(15)00266-2 10.1038/nature07830 10.1016/j.vaccine.2006.06.005 10.4049/jimmunol.0901474 10.1080/14760584.2017.1244484 10.1016/j.vaccine.2005.12.017 10.1146/annurev.biochem.71.110601.135414 10.1016/j.vaccine.2007.07.052 10.1016/j.addr.2008.12.008 10.1371/journal.pone.0002636 10.1016/j.smim.2018.05.001 10.1126/scitranslmed.aal2094 10.1073/pnas.0702403104 10.4049/jimmunol.165.3.1228 10.1016/S0264-410X(96)00073-4 10.1128/CDLI.7.6.899-903.2000 10.1016/j.imlet.2012.06.002 10.4161/hv.21407 10.1039/C8CS00028J 10.1038/nature06939 10.1007/978-1-4939-6445-1_2 10.1039/C6TB01131D 10.1016/0192-0561(86)90116-5 10.1038/s41541-018-0089-x 10.1016/j.vaccine.2014.07.052 10.1016/S0966-842X(02)02426-5 10.1002/1097-0215(20010601)92:5<703::AID-IJC1250>3.0.CO;2-5 10.1073/pnas.0813390106 10.1038/ncomms7565 10.1586/14760584.6.5.685 10.1093/infdis/jir615 10.1096/fj.11-184556 10.1371/journal.pone.0088979 10.1016/j.vaccine.2014.06.033 10.1021/acsami.7b05817 10.3389/fimmu.2017.00149 10.1189/jlb.70.6.849 10.1016/j.immuni.2009.02.005 10.1371/journal.pone.0041451 10.1016/j.vaccine.2009.01.091 10.1586/erv.12.140 10.1016/j.micinf.2007.08.002 10.1016/j.tips.2009.03.005 10.1371/journal.pone.0022273 10.1016/S0264-410X(00)00031-1 10.1182/blood.V88.1.202.202 10.1016/j.vaccine.2015.09.097 10.1002/smll.201201962 10.3389/fimmu.2013.00114 10.1042/BJ20090272 10.1002/1521-4141(200012)30:12<3591::AID-IMMU3591>3.0.CO;2-J 10.1016/j.immuni.2010.10.002 10.1016/0264-410X(94)90127-9 10.1086/319227 10.1021/jm990222b 10.1007/s11101-010-9183-z 10.1007/s10875-010-9490-6 10.1586/erv.10.174 10.1111/j.1708-8305.2009.00351.x 10.1371/journal.pone.0161730 10.1371/journal.pone.0046094 10.1146/annurev.immunol.20.100301.064842 |
| ContentType | Journal Article |
| Copyright | 2019 Elsevier Ltd Copyright © 2019 Elsevier Ltd. All rights reserved. 2019. Elsevier Ltd |
| Copyright_xml | – notice: 2019 Elsevier Ltd – notice: Copyright © 2019 Elsevier Ltd. All rights reserved. – notice: 2019. Elsevier Ltd |
| DBID | NPM AAYXX CITATION 3V. 7QL 7RV 7T2 7T5 7U9 7X7 7XB 88C 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9- K9. KB0 LK8 M0R M0S M0T M1P M2O M7N M7P MBDVC NAPCQ PQEST PQQKQ PQUKI Q9U 7X8 |
| DOI | 10.1016/j.vaccine.2019.04.055 |
| DatabaseName | PubMed CrossRef ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) ProQuest Nursing and Allied Health Journals Health and Safety Science Abstracts (Full archive) Immunology Abstracts Virology and AIDS Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection AUTh Library subscriptions: ProQuest Central ProQuest Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection (Proquest) (PQ_SDU_P3) Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences Consumer Database (Proquest) Health & Medical Collection (Alumni Edition) ProQuest Healthcare Administration Database PML(ProQuest Medical Library) ProQuest research library Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | PubMed CrossRef Research Library Prep ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) Environmental Sciences and Pollution Management ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Research Library Health & Safety Science Abstracts ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Central Basic ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) Immunology Abstracts ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Research Library Prep PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: AUTh Library subscriptions: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Veterinary Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1873-2518 |
| EndPage | 3178 |
| ExternalDocumentID | 10_1016_j_vaccine_2019_04_055 31047671 S0264410X19305298 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 53G 5RE 5VS 7-5 71M 7RV 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8P~ 9JM AAAJQ AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AAXUO ABBQC ABFNM ABFRF ABJNI ABKYH ABLVK ABMAC ABMZM ABRWV ABUWG ABYKQ ACDAQ ACGFO ACGFS ACIUM ACPRK ACRLP ADBBV ADEZE ADFRT AEBSH AEFWE AEKER AENEX AESVU AEVXI AEXOQ AFCTW AFKRA AFKWA AFRAH AFRHN AFTJW AFXIZ AGEKW AGGSO AGUBO AGYEJ AHMBA AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AQUVI AXJTR AZQEC BBNVY BENPR BHPHI BKEYQ BKNYI BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CJTIS CNWQP CS3 DWQXO EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K9- KOM L7B LCYCR LK8 LUGTX LW9 M0R M0T M1P M29 M2O M41 M7P MO0 N9A NAPCQ O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. PQQKQ PROAC PSQYO Q38 QYZTP RIG ROL RPZ SAB SCC SDF SDG SDP SES SNL SPCBC SSH SSI SSZ T5K UKHRP UV1 WH7 WOW Z5R ~G- AAHBH AAXKI AKRWK ALIPV NPM .GJ 0SF 29Q 3V. AAQXK AAYXX ABXDB ADMUD ADVLN AFJKZ AGHFR AHHHB ASPBG AVWKF AZFZN CITATION FEDTE FGOYB G-2 HEJ HLV HMG HMK HMO HVGLF HX~ HZ~ R2- SAE SEW SIN SVS WUQ XPP ZGI ZXP 7QL 7T2 7T5 7U9 7XB 8FK C1K H94 K9. M7N MBDVC PQEST PQUKI Q9U 7X8 |
| ID | FETCH-LOGICAL-c393t-e8f452e1171e5e48b39894ae2991b8f90d9d5c1f0ddab9d871701a9bfcbcaee23 |
| IEDL.DBID | 7X7 |
| ISSN | 0264-410X |
| IngestDate | Fri Oct 25 23:12:58 EDT 2024 Thu Oct 10 21:01:27 EDT 2024 Thu Sep 26 16:16:07 EDT 2024 Sat Sep 28 08:46:32 EDT 2024 Fri Feb 23 02:35:14 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 24 |
| Keywords | Aluminum salt Adjuvant Immunogenicity Structure-activity relationship |
| Language | English |
| License | Copyright © 2019 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c393t-e8f452e1171e5e48b39894ae2991b8f90d9d5c1f0ddab9d871701a9bfcbcaee23 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| ORCID | 0000-0002-5444-5078 |
| PMID | 31047671 |
| PQID | 2222595627 |
| PQPubID | 105530 |
| PageCount | 12 |
| ParticipantIDs | proquest_miscellaneous_2229235411 proquest_journals_2222595627 crossref_primary_10_1016_j_vaccine_2019_04_055 pubmed_primary_31047671 elsevier_sciencedirect_doi_10_1016_j_vaccine_2019_04_055 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-05-27 |
| PublicationDateYYYYMMDD | 2019-05-27 |
| PublicationDate_xml | – month: 05 year: 2019 text: 2019-05-27 day: 27 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands – name: Kidlington |
| PublicationTitle | Vaccine |
| PublicationTitleAlternate | Vaccine |
| PublicationYear | 2019 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | GlaxoSmithKline. CERVARIX [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine Kalimuddin, Wijaya, Chan, Wong, Oh, Wang (b0500) 2017; 35 He, Mitchell, Johnson, Wagner-Bartak, Morcol, Bell (b0540) 2000; 7 Aimanianda, Haensler, Lacroix-Desmazes, Kaveri, Bayry (b0065) 2009; 30 Klinman (b0300) 2004; 4 Seya, Matsumoto, Ebihara, Oshiumi (b0475) 2008; 227 Egwang, Befus (b0165) 1984; 51 Sun, Yu, Zhao, Guo, Wang, Zhao (b0565) 2018; 36 Kammer, Amacker, Rasi, Westerfeld, Gremion, Neuhaus (b0585) 2007; 25 Morel, Didierlaurent, Bourguignon, Delhaye, Baras, Jacob (b0245) 2011; 29 Wu, Ellis, Shaffer, Fontes, Malkin, Mahanty (b0435) 2008; 3 Cech, Aebi, Abdallah, Mpina, Machunda, Westerfeld (b0580) 2011; 6 Aucouturier, Dupuis, Deville, Ascarateil, Ganne (b0425) 2002; 1 Di Sabatino, Calarota, Vidali, MacDonald, Corazza (b0535) 2011; 22 Kommareddy, Singh, O'Hagan (b0185) 2017 Gupta, Chang, Griffin, Rivera, Siber (b0080) 1996; 14 Bennett, Yadava, Tosh, Sattabongkot, Komisar, Ware (b0635) 2016; 10 Flach, Ng, Hari, Desrosiers, Zhang, Ward (b0155) 2011; 17 Awate, Babiuk, Mutwiri (b0075) 2013; 4 Yam, Gupta, Winter, Allen, Brewer, Beaulieu (b0230) 2015; 6 Billiau, Matthys (b0170) 2001; 70 Allison, Gregoriadis (b0380) 1974; 252 Mayer, Armstrong, Kazanjian (b0620) 2001; 32 Terhune, Deth (b0150) 2014; 32 Podolak, Galanty, Sobolewska (b0460) 2010; 9 Francica, Sheng, Zhang, Nishimura, Shingai, Ramesh (b0655) 2015; 6 Sirima, Durier, Kara, Houard, Gansane, Loulergue (b0415) 2017; 35 Pichyangkul, Kum-Arb, Yongvanitchit, Limsalakpetch, Gettayacamin, Lanar (b0365) 2008; 76 < Berger Anderson R. Incorporation of CpG Oligodeoxynucleotides into α2-macroglobulin: development of a novel vaccine adjuvant delivery mechanism; 2018. Baden, Blattner, Morgan, Huang, Defawe, Sobieszczyk (b0605) 2011; 204 Li, Wang, Ito (b0070) 2018; 47 van Doorn, Liu, Huckriede, Hak (b0440) 2016; 12 Didierlaurent, Morel, Lockman, Giannini, Bisteau, Carlsen (b0345) 2009; 183 Al-Shakhshir, Regnier, White, Hem (b0055) 1994; 12 Glenny (b0030) 1930; 2 Ellis, Wu, Martin, Shaffer, Miura, Aebig (b0285) 2012; 7 Jalah, Patel, Kulkarni, Rosati, Alicea, Ganneru (b0505) 2012; 8 Gupta, Siber (b0375) 1995; 13 Coffman, Sher, Seder (b0555) 2010; 33 Seubert, Monaci, Pizza, O’Hagan, Wack (b0205) 2008; 180 Moris, van der Most, Leroux-Roels, Clement, Dramé, Hanon (b0250) 2011; 31 Burrell, White, Hem (b0090) 2000; 18 Hutchison, Benson, Gibson, Pollock, Garside, Brewer (b0085) 2012; 26 Cooper CL, Davis H, Angel JB, Lou Morris M, Elfer SM, Seguin I, et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults; 2005. Caulfield, Shi, Wang, Wang, Tobery, Mach (b0050) 2014; 3 Kaliński, Hilkens, Wierenga, Kapsenberg (b0145) 1999; 20 Huleatt, Jacobs, Tang, Desai, Kopp, Huang (b0550) 2007; 25 Garçon, Vaughn, Didierlaurent (b0240) 2012; 11 Pillet, Aubin, Trépanier, Poulin, Yassine-Diab, ter Meulen (b0410) 2018; 3 Krieg A, Yi A-K, Matson S, Waldschmidt TJ, Bishop G, Teasdale R, et al. CpG motifs in bacterial DNA trigger direct B-cell activation; 1995. Del Giudice, Rappuoli, Didierlaurent (b0340) 2018 Disis, Bernhard, Shiota, Hand, Gralow, Huseby (b0525) 1996; 88 Masson J-D, Thibaudon M, Bélec L, Crepeaux G. Calcium phosphate: a substitute for aluminum adjuvants; 2016. Ghimire, Benson, Garside, Brewer (b0110) 2012; 147 Bode, Zhao, Steinhagen, Kinjo, Klinman (b0270) 2011; 10 Zhu, Tuo (b0360) 2016; 3 Johnson, Keegan, Sowell, Livesay, Johnson, Taubner (b0395) 1999; 42 Kester, Gray Heppner, Moris, Ofori-Anyinam, Krzych, Tornieporth (b0470) 2014; 32 Frösner, Steffen, Herzog (b0640) 2009; 16 Reimer, Karlsson, Lövgren-Bengtsson, Magnusson, Fuentes, Stertman (b0465) 2012; 7 Sun, Ji, Liao, Chang, Wang, Ku (b0130) 2017; 9 Hem, HogenEsch (b0140) 2007; 6 Medicine USNLo. A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, With Matrix-M1 Adjuvant. O’Hagan D, Ott GS, Van Nest G, Rappuoli R, Del Giudice G. The history of MF59 (R) adjuvant: a phoenix that arose from the ashes; 2013. Persing, Coler, Lacy, Johnson, Baldridge, Hershberg (b0390) 2002; 10 Zhang, Wang, Wang (b0520) 2011; 8 Li P, Wang F. Polysaccharides: candidates of promising vaccine adjuvants; 2015. el Kassas H, Kirkwood JM. Adjuvant application of interferons. Ascarateil, Puget, Koziol (b0445) 2015; 3 Sun, Ji, Liao, Wang, Wang, Dong (b0045) 2013; 7 Vollmer, Krieg (b0275) 2009; 61 Döring, Meisner, Stern (b0560) 2007; 104 Lipford, Sparwasser, Zimmermann, Heeg, Wagner (b0295) 2000; 165 Walls (b0095) 1977; 156 Ramanathan V, Badenoch-Jones P, Turk JL. Complement activation by aluminum and zirconium compounds; 1979. Medicine USNLo. The Treatment With HBIG+GM-CSF+HBV Vaccine for Chronic Hepatitis B Patients With HBeAg Seroconversion. Aravantinou, Frank, Hallor, Singer, Tharinger, Kenney (b0610) 2016; 11 Sun, Xie, Ye (b0455) 2009; 27 Franchi L, Nunez G. The Nlrp3 inflammasome is critical for aluminum hydroxide-mediated IL-1β secretion but dispensable for adjuvant activity; 2008. Sparwasser T, Vabulas RM, Villmow B, Lipford G, Wagner H. Bacterial CpG‐DNA activates dendritic cells in vivo: T helper cell‐independent cytotoxic T cell responses to soluble proteins; 2000. Bangham, Standish, Miller (b0385) 1965; 208 Lee, Wang, Kuniyoshi, Rubio, Stuge, Groshen (b0430) 2001; 19 O’Hagan, Ott, De Gregorio, Seubert (b0210) 2012; 30 Jacobson, Zheng, Wilson, Tebas, Matining, Egan (b0600) 1999; 2016 [accessed 31 March, 2019]. Garçon, Chomez, Van Mechelen (b0325) 2007; 6 Sun, Xia (b0035) 2016; 4 Eisenbarth S, O'Connor W, Sutterwala F, Flavell R. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants; 2008. Galli, Medini, Borgogni, Zedda, Bardelli, Malzone (b0195) 2009; 106 Moser, Metcalfe, Viret (b0570) 2003; 2 Allen, Scull, Moore, Holl, McElvania-TeKippe, Taxman (b0490) 2009; 30 Herbert (b0200) 1966; 210 Raetz, Whitfield (b0400) 2002; 71 Cioncada, Maddaluno, Vo, Woodruff, Tavarini, Sammicheli (b0215) 2017; 12 Giannini, Hanon, Moris, Van Mechelen, Morel, Dessy (b0335) 2006; 24 Campbell (b0280) 2017; 1494 Joseph, Itskovitz-Cooper, Samira, Flasterstein, Eliyahu, Simberg (b0590) 2006; 24 Hogenesch H. Mechanisms of stimulation of immune response by aluminium adjuvants; 2002. Liebowitz, Lindbloom, Brandl, Garg, Tucker (b0495) 2015; 15 Yamshchikov, Barnd, Eastham, Galavotti, Patterson, Deacon (b0450) 2001; 92 Wu, Narum, Fleury, Jennings, Yadava (b0235) 2015; 33 Joseph, Quinn, Greenwood, Cope, McKay, Hayes (b0420) 2017; 8 Masson, Thibaudon, Bélec, Crépeaux (b0545) 2017; 16 Sun, Wang, Ji, Li, Xia (b0120) 2013; 9 Kumar, Kawai, Akira (b0480) 2009; 420 Hogenesch (b0040) 2012; 3 Gupta (b0025) 1998; 32 Moser, Amacker, Zurbriggen (b0575) 2011; 10 Vandepapelière, Horsmans, Moris, Van Mechelen, Janssens, Koutsoukos (b0370) 2008; 26 Liang, Lindgren, Sandgren, Thompson, Francica, Seubert (b0650) 2017; 9 Baca-Estrada, Foldvari, Snider (b0530) 1999; 19 Vo, Baudner, Sammicheli, Iannacone, D’Oro, Piccioli (b0645) 2018; 9 Fang, Hora (b0190) 2000 Sokolovska, Hem, HogenEsch (b0115) 2007; 25 Noel Masihi, Lange, Brehmer, Ribi (b0180) 1986; 8 Kalams, Parker, Jin, Elizaga, Metch, Wang (b0510) 2012; 7 Recombinant]; 2018. Didierlaurent, Laupèze, Di Pasquale, Hergli, Collignon, Garçon (b0355) 2017; 16 HogenEsch, O'Hagan, Fox (b0060) 2018; 3 Klinman, Currie, Lee, Grippe, Merkel (b0315) 2007; 9 Clegg, Roque, Perrone, Rininger, Bowen, Reed (b0405) 2014; 9 Gordon, Sajkov, Honda-Okubo, Wilks, Aban, Barr (b0625) 2016; 34 Jin, Sun, Yu, Liu, Yang, Lu (b0485) 2010.; 2010 Mannhalter, Neychev, Zlabinger, Ahmad, Eibl (b0105) 1985; 61 Technology DD. Pandemrix-Adjuvanted H1N1 Inluenza Vaccine; 2017. Scheiermann, Klinman (b0265) 2014; 32 Park, Song, Kim, Choi, Lee, Lee (b0330) 2009; 458 Krieg (b0305) 2002; 20 Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults. GlaxoSmithKline. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted; 2018. Hutchison (10.1016/j.vaccine.2019.04.055_b0085) 2012; 26 Gupta (10.1016/j.vaccine.2019.04.055_b0025) 1998; 32 Aravantinou (10.1016/j.vaccine.2019.04.055_b0610) 2016; 11 10.1016/j.vaccine.2019.04.055_b0310 Hogenesch (10.1016/j.vaccine.2019.04.055_b0040) 2012; 3 Moser (10.1016/j.vaccine.2019.04.055_b0575) 2011; 10 Terhune (10.1016/j.vaccine.2019.04.055_b0150) 2014; 32 Didierlaurent (10.1016/j.vaccine.2019.04.055_b0355) 2017; 16 Klinman (10.1016/j.vaccine.2019.04.055_b0300) 2004; 4 Bennett (10.1016/j.vaccine.2019.04.055_b0635) 2016; 10 Giannini (10.1016/j.vaccine.2019.04.055_b0335) 2006; 24 Walls (10.1016/j.vaccine.2019.04.055_b0095) 1977; 156 Yamshchikov (10.1016/j.vaccine.2019.04.055_b0450) 2001; 92 Frösner (10.1016/j.vaccine.2019.04.055_b0640) 2009; 16 Fang (10.1016/j.vaccine.2019.04.055_b0190) 2000 Yam (10.1016/j.vaccine.2019.04.055_b0230) 2015; 6 10.1016/j.vaccine.2019.04.055_b0160 Sirima (10.1016/j.vaccine.2019.04.055_b0415) 2017; 35 Jacobson (10.1016/j.vaccine.2019.04.055_b0600) 1999; 2016 Aucouturier (10.1016/j.vaccine.2019.04.055_b0425) 2002; 1 van Doorn (10.1016/j.vaccine.2019.04.055_b0440) 2016; 12 Allison (10.1016/j.vaccine.2019.04.055_b0380) 1974; 252 10.1016/j.vaccine.2019.04.055_b0320 Vo (10.1016/j.vaccine.2019.04.055_b0645) 2018; 9 Raetz (10.1016/j.vaccine.2019.04.055_b0400) 2002; 71 Kalimuddin (10.1016/j.vaccine.2019.04.055_b0500) 2017; 35 Kommareddy (10.1016/j.vaccine.2019.04.055_b0185) 2017 Di Sabatino (10.1016/j.vaccine.2019.04.055_b0535) 2011; 22 Didierlaurent (10.1016/j.vaccine.2019.04.055_b0345) 2009; 183 Krieg (10.1016/j.vaccine.2019.04.055_b0305) 2002; 20 Sokolovska (10.1016/j.vaccine.2019.04.055_b0115) 2007; 25 10.1016/j.vaccine.2019.04.055_b0290 Burrell (10.1016/j.vaccine.2019.04.055_b0090) 2000; 18 10.1016/j.vaccine.2019.04.055_b0175 Sun (10.1016/j.vaccine.2019.04.055_b0455) 2009; 27 Galli (10.1016/j.vaccine.2019.04.055_b0195) 2009; 106 He (10.1016/j.vaccine.2019.04.055_b0540) 2000; 7 Cech (10.1016/j.vaccine.2019.04.055_b0580) 2011; 6 Pichyangkul (10.1016/j.vaccine.2019.04.055_b0365) 2008; 76 Cioncada (10.1016/j.vaccine.2019.04.055_b0215) 2017; 12 Zhang (10.1016/j.vaccine.2019.04.055_b0520) 2011; 8 10.1016/j.vaccine.2019.04.055_b0220 10.1016/j.vaccine.2019.04.055_b0100 Baden (10.1016/j.vaccine.2019.04.055_b0605) 2011; 204 Campbell (10.1016/j.vaccine.2019.04.055_b0280) 2017; 1494 Jalah (10.1016/j.vaccine.2019.04.055_b0505) 2012; 8 10.1016/j.vaccine.2019.04.055_b0225 10.1016/j.vaccine.2019.04.055_b0615 Al-Shakhshir (10.1016/j.vaccine.2019.04.055_b0055) 1994; 12 Baca-Estrada (10.1016/j.vaccine.2019.04.055_b0530) 1999; 19 Moser (10.1016/j.vaccine.2019.04.055_b0570) 2003; 2 Gupta (10.1016/j.vaccine.2019.04.055_b0375) 1995; 13 Wu (10.1016/j.vaccine.2019.04.055_b0435) 2008; 3 Liang (10.1016/j.vaccine.2019.04.055_b0650) 2017; 9 HogenEsch (10.1016/j.vaccine.2019.04.055_b0060) 2018; 3 Joseph (10.1016/j.vaccine.2019.04.055_b0590) 2006; 24 Huleatt (10.1016/j.vaccine.2019.04.055_b0550) 2007; 25 Mayer (10.1016/j.vaccine.2019.04.055_b0620) 2001; 32 Persing (10.1016/j.vaccine.2019.04.055_b0390) 2002; 10 Seya (10.1016/j.vaccine.2019.04.055_b0475) 2008; 227 Francica (10.1016/j.vaccine.2019.04.055_b0655) 2015; 6 10.1016/j.vaccine.2019.04.055_b0350 Sun (10.1016/j.vaccine.2019.04.055_b0130) 2017; 9 Flach (10.1016/j.vaccine.2019.04.055_b0155) 2011; 17 10.1016/j.vaccine.2019.04.055_b0595 10.1016/j.vaccine.2019.04.055_b0630 Li (10.1016/j.vaccine.2019.04.055_b0070) 2018; 47 Caulfield (10.1016/j.vaccine.2019.04.055_b0050) 2014; 3 Kammer (10.1016/j.vaccine.2019.04.055_b0585) 2007; 25 Lee (10.1016/j.vaccine.2019.04.055_b0430) 2001; 19 Sun (10.1016/j.vaccine.2019.04.055_b0565) 2018; 36 Scheiermann (10.1016/j.vaccine.2019.04.055_b0265) 2014; 32 Bode (10.1016/j.vaccine.2019.04.055_b0270) 2011; 10 Kumar (10.1016/j.vaccine.2019.04.055_b0480) 2009; 420 Gupta (10.1016/j.vaccine.2019.04.055_b0080) 1996; 14 Sun (10.1016/j.vaccine.2019.04.055_b0035) 2016; 4 Wu (10.1016/j.vaccine.2019.04.055_b0235) 2015; 33 Gordon (10.1016/j.vaccine.2019.04.055_b0625) 2016; 34 Noel Masihi (10.1016/j.vaccine.2019.04.055_b0180) 1986; 8 Sun (10.1016/j.vaccine.2019.04.055_b0045) 2013; 7 O’Hagan (10.1016/j.vaccine.2019.04.055_b0210) 2012; 30 Lipford (10.1016/j.vaccine.2019.04.055_b0295) 2000; 165 10.1016/j.vaccine.2019.04.055_b0125 10.1016/j.vaccine.2019.04.055_b0005 Allen (10.1016/j.vaccine.2019.04.055_b0490) 2009; 30 Döring (10.1016/j.vaccine.2019.04.055_b0560) 2007; 104 10.1016/j.vaccine.2019.04.055_b0515 Podolak (10.1016/j.vaccine.2019.04.055_b0460) 2010; 9 Jin (10.1016/j.vaccine.2019.04.055_b0485) 2010; 2010 Del Giudice (10.1016/j.vaccine.2019.04.055_b0340) 2018 Clegg (10.1016/j.vaccine.2019.04.055_b0405) 2014; 9 Disis (10.1016/j.vaccine.2019.04.055_b0525) 1996; 88 Hem (10.1016/j.vaccine.2019.04.055_b0140) 2007; 6 Liebowitz (10.1016/j.vaccine.2019.04.055_b0495) 2015; 15 Morel (10.1016/j.vaccine.2019.04.055_b0245) 2011; 29 Kalams (10.1016/j.vaccine.2019.04.055_b0510) 2012; 7 Herbert (10.1016/j.vaccine.2019.04.055_b0200) 1966; 210 10.1016/j.vaccine.2019.04.055_b0010 Kaliński (10.1016/j.vaccine.2019.04.055_b0145) 1999; 20 10.1016/j.vaccine.2019.04.055_b0255 10.1016/j.vaccine.2019.04.055_b0135 10.1016/j.vaccine.2019.04.055_b0015 Billiau (10.1016/j.vaccine.2019.04.055_b0170) 2001; 70 Klinman (10.1016/j.vaccine.2019.04.055_b0315) 2007; 9 Coffman (10.1016/j.vaccine.2019.04.055_b0555) 2010; 33 Seubert (10.1016/j.vaccine.2019.04.055_b0205) 2008; 180 Egwang (10.1016/j.vaccine.2019.04.055_b0165) 1984; 51 Park (10.1016/j.vaccine.2019.04.055_b0330) 2009; 458 Awate (10.1016/j.vaccine.2019.04.055_b0075) 2013; 4 Garçon (10.1016/j.vaccine.2019.04.055_b0240) 2012; 11 Ascarateil (10.1016/j.vaccine.2019.04.055_b0445) 2015; 3 Garçon (10.1016/j.vaccine.2019.04.055_b0325) 2007; 6 Zhu (10.1016/j.vaccine.2019.04.055_b0360) 2016; 3 Johnson (10.1016/j.vaccine.2019.04.055_b0395) 1999; 42 Mannhalter (10.1016/j.vaccine.2019.04.055_b0105) 1985; 61 Aimanianda (10.1016/j.vaccine.2019.04.055_b0065) 2009; 30 10.1016/j.vaccine.2019.04.055_b0260 Glenny (10.1016/j.vaccine.2019.04.055_b0030) 1930; 2 10.1016/j.vaccine.2019.04.055_b0020 Kester (10.1016/j.vaccine.2019.04.055_b0470) 2014; 32 Bangham (10.1016/j.vaccine.2019.04.055_b0385) 1965; 208 Vollmer (10.1016/j.vaccine.2019.04.055_b0275) 2009; 61 Moris (10.1016/j.vaccine.2019.04.055_b0250) 2011; 31 Sun (10.1016/j.vaccine.2019.04.055_b0120) 2013; 9 Ghimire (10.1016/j.vaccine.2019.04.055_b0110) 2012; 147 Joseph (10.1016/j.vaccine.2019.04.055_b0420) 2017; 8 Pillet (10.1016/j.vaccine.2019.04.055_b0410) 2018; 3 Ellis (10.1016/j.vaccine.2019.04.055_b0285) 2012; 7 Vandepapelière (10.1016/j.vaccine.2019.04.055_b0370) 2008; 26 Masson (10.1016/j.vaccine.2019.04.055_b0545) 2017; 16 Reimer (10.1016/j.vaccine.2019.04.055_b0465) 2012; 7 |
| References_xml | – volume: 7 start-page: e29231 year: 2012 ident: b0510 article-title: Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine with or without IL-12 and/or IL-15 Plasmid Cytokine Adjuvant in Healthy, HIV-1 Uninfected Adults publication-title: PLoS ONE contributor: fullname: Wang – volume: 19 start-page: 3836 year: 2001 end-page: 3847 ident: b0430 article-title: Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma publication-title: J Clin Oncol contributor: fullname: Groshen – volume: 210 start-page: 747 year: 1966 ident: b0200 article-title: Antigenicity of soluble protein in the presence of high levels of antibody : a possible mode of action of the antigen adjuvants publication-title: Nature contributor: fullname: Herbert – volume: 25 start-page: 7065 year: 2007 end-page: 7074 ident: b0585 article-title: A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses publication-title: Vaccine contributor: fullname: Neuhaus – volume: 2 start-page: 189 year: 2003 end-page: 196 ident: b0570 article-title: Virosomal adjuvanted antigen delivery systems publication-title: Expert Rev Vacc contributor: fullname: Viret – volume: 51 start-page: 207 year: 1984 end-page: 224 ident: b0165 article-title: The role of complement in the induction and regulation of immune responses publication-title: Immunology contributor: fullname: Befus – volume: 3 start-page: e113 year: 2016 ident: b0360 article-title: QS-21: a potent vaccine adjuvant publication-title: Natural Products Chem Res contributor: fullname: Tuo – volume: 26 start-page: 1375 year: 2008 end-page: 1386 ident: b0370 article-title: Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers publication-title: Vaccine contributor: fullname: Koutsoukos – volume: 16 start-page: 289 year: 2017 end-page: 299 ident: b0545 article-title: Calcium phosphate: a substitute for aluminum adjuvants? publication-title: Expert Rev Vacc contributor: fullname: Crépeaux – volume: 20 start-page: 561 year: 1999 end-page: 567 ident: b0145 article-title: T-cell priming by type-1and type-2 polarized dendritic cells: the concept of a third signal publication-title: Immunol Today contributor: fullname: Kapsenberg – volume: 104 start-page: 11020 year: 2007 ident: b0560 article-title: A double-blind randomized placebo-controlled phase III study of a <em>Pseudomonas aeruginosa</em> flagella vaccine in cystic fibrosis patients publication-title: Proc Natl Acad Sci contributor: fullname: Stern – volume: 29 start-page: 2461 year: 2011 end-page: 2473 ident: b0245 article-title: Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity publication-title: Vaccine contributor: fullname: Jacob – volume: 92 start-page: 703 year: 2001 end-page: 711 ident: b0450 article-title: Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients publication-title: Int J Cancer contributor: fullname: Deacon – volume: 33 start-page: 492 year: 2010 end-page: 503 ident: b0555 article-title: Vaccine adjuvants: putting innate immunity to work publication-title: Immunity contributor: fullname: Seder – volume: 204 start-page: 1541 year: 2011 end-page: 1549 ident: b0605 article-title: Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects publication-title: J Infect Dis contributor: fullname: Sobieszczyk – volume: 147 start-page: 55 year: 2012 end-page: 62 ident: b0110 article-title: Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro publication-title: Immunol Lett contributor: fullname: Brewer – volume: 12 start-page: 159 year: 2016 end-page: 169 ident: b0440 article-title: Safety and tolerability evaluation of the use of Montanide ISA™51 as vaccine adjuvant: a systematic review publication-title: Human Vacc Immunotherapeutics contributor: fullname: Hak – volume: 32 start-page: 155 year: 1998 end-page: 172 ident: b0025 article-title: Aluminum compounds as vaccine adjuvants publication-title: Adv Drug Deliv Rev contributor: fullname: Gupta – volume: 183 start-page: 6186 year: 2009 ident: b0345 article-title: AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity publication-title: J Immunol contributor: fullname: Carlsen – volume: 9 start-page: 1478 year: 2007 end-page: 1483 ident: b0315 article-title: Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax publication-title: Microbes Infect contributor: fullname: Merkel – volume: 7 start-page: 899 year: 2000 end-page: 903 ident: b0540 article-title: Calcium phosphate nanoparticle adjuvant publication-title: Clin Diagn Lab Immunol contributor: fullname: Bell – volume: 30 start-page: 556 year: 2009 end-page: 565 ident: b0490 article-title: The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA publication-title: Immunity contributor: fullname: Taxman – volume: 26 start-page: 1272 year: 2012 end-page: 1279 ident: b0085 article-title: Antigen depot is not required for alum adjuvanticity publication-title: FASEB J contributor: fullname: Brewer – volume: 12 start-page: 472 year: 1994 end-page: 474 ident: b0055 article-title: Effect of protein adsorption on the surface charge characteristics of aluminium-containing adjuvants publication-title: Vaccine contributor: fullname: Hem – volume: 61 start-page: 195 year: 2009 end-page: 204 ident: b0275 article-title: Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists publication-title: Adv Drug Deliv Rev contributor: fullname: Krieg – volume: 156 start-page: 431 year: 1977 end-page: 435 ident: b0095 article-title: Eosinophil response to alum adjuvants: involvement of t cells in non-antigen-dependent mechanisms publication-title: Proce Soc Experimental Biol Med contributor: fullname: Walls – volume: 8 start-page: 339 year: 1986 end-page: 345 ident: b0180 article-title: Immunobiological activities of nontoxic lipid A: enhancement of nonspecific resistance in combination with trehalose dimycolate against viral infection and adjuvant effects publication-title: Int J Immunopharmacol contributor: fullname: Ribi – volume: 9 start-page: e88979 year: 2014 ident: b0405 article-title: GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza publication-title: PLoS ONE contributor: fullname: Reed – volume: 19 start-page: 455 year: 1999 end-page: 462 ident: b0530 article-title: Induction of mucosal immune responses by administration of liposome-antigen formulations and interleukin-12 publication-title: J Interferon Cytokine Res contributor: fullname: Snider – volume: 7 start-page: 10834 year: 2013 end-page: 10849 ident: b0045 article-title: Engineering an effective immune adjuvant by designed control of shape and crystallinity of aluminum oxyhydroxide nanoparticles publication-title: ACS Nano contributor: fullname: Dong – volume: 458 start-page: 1191 year: 2009 ident: b0330 article-title: The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex publication-title: Nature contributor: fullname: Lee – volume: 1 start-page: 111 year: 2002 end-page: 118 ident: b0425 article-title: Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines publication-title: Expert Rev Vacc contributor: fullname: Ganne – volume: 3 start-page: 406 year: 2012 ident: b0040 article-title: Mechanism of immunopotentiation and safety of aluminum adjuvants publication-title: Front Immunol. contributor: fullname: Hogenesch – volume: 71 start-page: 635 year: 2002 end-page: 700 ident: b0400 article-title: Lipopolysaccharide endotoxins publication-title: Annu Rev Biochem contributor: fullname: Whitfield – volume: 10 start-page: 437 year: 2011 end-page: 446 ident: b0575 article-title: Influenza virosomes as a vaccine adjuvant and carrier system publication-title: Expert Rev Vacc contributor: fullname: Zurbriggen – volume: 33 start-page: 7518 year: 2015 end-page: 7524 ident: b0235 article-title: Particle-based platforms for malaria vaccines publication-title: Vaccine contributor: fullname: Yadava – volume: 31 start-page: 443 year: 2011 end-page: 454 ident: b0250 article-title: H5N1 influenza vaccine formulated with AS03A induces strong cross-reactive and polyfunctional CD4 T-cell responses publication-title: J Clin Immunol contributor: fullname: Hanon – volume: 24 start-page: 3990 year: 2006 end-page: 4006 ident: b0590 article-title: A new intranasal influenza vaccine based on a novel polycationic lipid—ceramide carbamoyl-spermine (CCS): I. Immunogenicity and efficacy studies in mice publication-title: Vaccine contributor: fullname: Simberg – volume: 16 start-page: 413 year: 2009 end-page: 419 ident: b0640 article-title: Virosomal hepatitis A vaccine: comparing intradermal and subcutaneous with intramuscular administration publication-title: J Travel Med contributor: fullname: Herzog – volume: 208 start-page: 1295 year: 1965 ident: b0385 article-title: Cation permeability of phospholipid model membranes: effect of narcotics publication-title: Nature contributor: fullname: Miller – volume: 32 start-page: 766 year: 2001 end-page: 773 ident: b0620 article-title: Use of cytokines in human immunodeficiency virus-infected patients: colony-stimulating factors, erythropoietin, and interleukin-2 publication-title: Clin Infect Dis contributor: fullname: Kazanjian – volume: 2010 year: 2010. ident: b0485 article-title: Immunomodulatory Effects of dsRNA and Its Potential as Vaccine Adjuvant %J publication-title: J Biomed Biotechnol contributor: fullname: Lu – volume: 9 start-page: 1595 year: 2013 end-page: 1607 ident: b0120 article-title: NLRP3 inflammasome activation induced by engineered nanomaterials publication-title: Small contributor: fullname: Xia – volume: 6 start-page: 723 year: 2007 end-page: 739 ident: b0325 article-title: GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives publication-title: Expert Rev Vacc contributor: fullname: Van Mechelen – volume: 9 year: 2018 ident: b0645 article-title: Alum/toll-like receptor 7 adjuvant enhances the expansion of memory B cell compartment within the draining lymph node publication-title: Front Immunol contributor: fullname: Piccioli – volume: 22 start-page: 19 year: 2011 end-page: 33 ident: b0535 article-title: Role of IL-15 in immune-mediated and infectious diseases publication-title: Cytokine Growth Factor Rev contributor: fullname: Corazza – volume: 10 start-page: s32 year: 2002 end-page: s37 ident: b0390 article-title: Taking toll: lipid A mimetics as adjuvants and immunomodulators publication-title: Trends Microbiol contributor: fullname: Hershberg – volume: 2016 start-page: 163 year: 1999 end-page: 171 ident: b0600 article-title: The safety and immunogenicity of an interleukin-12-enhanced multiantigen DNA vaccine delivered by electroporation for the treatment of HIV-1 infection publication-title: J Acquir Immune Defic Syndr contributor: fullname: Egan – start-page: 249 year: 2017 end-page: 263 ident: b0185 article-title: Chapter 13 - MF59: a safe and potent adjuvant for publication-title: Immunopotentiators in Modern Vaccines (Second Edition) contributor: fullname: O'Hagan – volume: 7 start-page: e46094 year: 2012 ident: b0285 article-title: Phase 1 study in malaria naïve adults of BSAM2/alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum Malaria publication-title: PLOS One contributor: fullname: Aebig – volume: 17 start-page: 479 year: 2011 end-page: 487 ident: b0155 article-title: Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity publication-title: Nat Med contributor: fullname: Ward – volume: 3 start-page: 3 year: 2018 ident: b0410 article-title: Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a Phase 2 clinical trial publication-title: npj Vaccines contributor: fullname: ter Meulen – volume: 25 start-page: 763 year: 2007 end-page: 775 ident: b0550 article-title: Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity publication-title: Vaccine contributor: fullname: Huang – volume: 12 start-page: e0185843 year: 2017 ident: b0215 article-title: Vaccine adjuvant MF59 promotes the intranodal differentiation of antigen-loaded and activated monocyte-derived dendritic cells publication-title: PLoS ONE contributor: fullname: Sammicheli – volume: 2 start-page: 244 year: 1930 ident: b0030 article-title: Insoluble precipitates in diphtheria and tetanus immunization publication-title: Br Med J contributor: fullname: Glenny – volume: 106 start-page: 3877 year: 2009 ident: b0195 article-title: H5N1 vaccine induces early CD4<sup>+</sup> T cell response that predicts long-term persistence of protective antibody levels publication-title: Proc Natl Acad Sci contributor: fullname: Malzone – volume: 30 start-page: 287 year: 2009 end-page: 295 ident: b0065 article-title: Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants publication-title: Trends Pharmacol Sci contributor: fullname: Bayry – volume: 18 start-page: 2188 year: 2000 end-page: 2192 ident: b0090 article-title: Stability of aluminium-containing adjuvants during aging at room temperature publication-title: Vaccine contributor: fullname: Hem – volume: 36 start-page: 5226 year: 2018 end-page: 5234 ident: b0565 article-title: Polysaccharides as vaccine adjuvants publication-title: Vaccine contributor: fullname: Zhao – volume: 32 start-page: 5149 year: 2014 end-page: 5155 ident: b0150 article-title: A role for impaired regulatory T cell function in adverse responses to aluminum adjuvant-containing vaccines in genetically susceptible individuals publication-title: Vaccine contributor: fullname: Deth – volume: 6 year: 2015 ident: b0655 article-title: Analysis of immunoglobulin transcripts and hypermutation following SHIVAD8 infection and protein-plus-adjuvant immunization publication-title: Nature Commun contributor: fullname: Ramesh – volume: 25 start-page: 4575 year: 2007 end-page: 4585 ident: b0115 article-title: Activation of dendritic cells and induction of CD4+ T cell differentiation by aluminum-containing adjuvants publication-title: Vaccine contributor: fullname: HogenEsch – volume: 420 start-page: 1 year: 2009 ident: b0480 article-title: Pathogen recognition in the innate immune response publication-title: Biochem J contributor: fullname: Akira – volume: 4 start-page: 5496 year: 2016 end-page: 5509 ident: b0035 article-title: Nanomaterial-based vaccine adjuvants publication-title: J Mater Chem B contributor: fullname: Xia – volume: 9 year: 2017 ident: b0650 article-title: Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake publication-title: Sci Transl Med contributor: fullname: Seubert – volume: 32 start-page: 6683 year: 2014 end-page: 6691 ident: b0470 article-title: Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS, S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults publication-title: Vaccine contributor: fullname: Tornieporth – volume: 227 start-page: 44 year: 2008 end-page: 53 ident: b0475 article-title: Functional evolution of the TICAM-1 pathway for extrinsic RNA sensing publication-title: Immunol Rev contributor: fullname: Oshiumi – volume: 3 start-page: e2636 year: 2008 ident: b0435 article-title: Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51 publication-title: PLoS One contributor: fullname: Mahanty – volume: 42 start-page: 4640 year: 1999 end-page: 4649 ident: b0395 article-title: 3-O-Desacyl monophosphoryl lipid A derivatives: synthesis and immunostimulant activities publication-title: J Med Chem contributor: fullname: Taubner – volume: 32 start-page: 6377 year: 2014 end-page: 6389 ident: b0265 article-title: Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer publication-title: Vaccine contributor: fullname: Klinman – volume: 6 start-page: 685 year: 2007 end-page: 698 ident: b0140 article-title: Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation publication-title: Expert Rev Vacc contributor: fullname: HogenEsch – year: 2018 ident: b0340 article-title: Correlates of adjuvanticity: A review on adjuvants in licensed vaccines publication-title: Semin Immunol contributor: fullname: Didierlaurent – volume: 11 start-page: 349 year: 2012 end-page: 366 ident: b0240 article-title: Development and evaluation of AS03, an adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion publication-title: Expert Rev Vacc contributor: fullname: Didierlaurent – start-page: 211 year: 2000 end-page: 228 ident: b0190 article-title: The adjuvant MF59: A 10-Year perspective Gary Ott, Ramachandran Radhakrishnan publication-title: Vaccine adjuvants: preparation methods and research protocols contributor: fullname: Hora – volume: 9 start-page: 425 year: 2010 end-page: 474 ident: b0460 article-title: Saponins as cytotoxic agents: a review publication-title: Phytochem Rev contributor: fullname: Sobolewska – volume: 13 start-page: 1263 year: 1995 end-page: 1276 ident: b0375 article-title: Adjuvants for human vaccines—current status, problems and future prospects publication-title: Vaccine contributor: fullname: Siber – volume: 3 start-page: 139 year: 2014 end-page: 145 ident: b0050 article-title: Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice publication-title: Human Vacc contributor: fullname: Mach – volume: 15 start-page: 1041 year: 2015 end-page: 1048 ident: b0495 article-title: High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial publication-title: Lancet Infect Dis contributor: fullname: Tucker – volume: 180 start-page: 5402 year: 2008 ident: b0205 article-title: The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells publication-title: J Immunol contributor: fullname: Wack – volume: 10 start-page: 499 year: 2011 end-page: 511 ident: b0270 article-title: CpG DNA as a vaccine adjuvant publication-title: Expert Rev Vacc contributor: fullname: Klinman – volume: 252 start-page: 252 year: 1974 ident: b0380 article-title: Liposomes as immunological adjuvants publication-title: Nature contributor: fullname: Gregoriadis – volume: 27 start-page: 1787 year: 2009 end-page: 1796 ident: b0455 article-title: Advances in saponin-based adjuvants publication-title: Vaccine. contributor: fullname: Ye – volume: 76 start-page: 229 year: 2008 ident: b0365 article-title: Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of <em>plasmodium falciparum</em> liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS, S/AS01B vaccine in rhesus primates publication-title: Infect Immun contributor: fullname: Lanar – volume: 6 start-page: e22273 year: 2011 ident: b0580 article-title: Virosome-formulated plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children publication-title: PLoS One contributor: fullname: Westerfeld – volume: 10 start-page: e0004423 year: 2016 ident: b0635 article-title: Phase 1/2a trial of plasmodium vivax malaria vaccine candidate VMP001/AS01B in malaria-naive adults: safety, immunogenicity, and efficacy publication-title: PLoS NeglTrop Dis contributor: fullname: Ware – volume: 61 start-page: 143 year: 1985 end-page: 151 ident: b0105 article-title: Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation publication-title: Clin Exp Immunol contributor: fullname: Eibl – volume: 4 start-page: 114 year: 2013 ident: b0075 article-title: Mechanisms of action of adjuvants publication-title: Front Immunol contributor: fullname: Mutwiri – volume: 3 year: 2018 ident: b0060 article-title: Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want publication-title: NPJ Vaccines contributor: fullname: Fox – volume: 35 start-page: 6218 year: 2017 end-page: 6227 ident: b0415 article-title: Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: a phase 1a/1b, randomized, double-blind multi-centre trial publication-title: Vaccine contributor: fullname: Loulergue – volume: 47 start-page: 4954 year: 2018 end-page: 4980 ident: b0070 article-title: Tailoring inorganic nanoadjuvants towards next-generation vaccines publication-title: Chem Soc Rev contributor: fullname: Ito – volume: 9 start-page: 21697 year: 2017 end-page: 21705 ident: b0130 article-title: Enhanced immune adjuvant activity of aluminum oxyhydroxide nanorods through cationic surface functionalization publication-title: ACS Appl Mater Interfaces contributor: fullname: Ku – volume: 70 start-page: 849 year: 2001 end-page: 860 ident: b0170 article-title: Modes of action of Freund’s adjuvants in experimental models of autoimmune diseases publication-title: J Leukoc Biol contributor: fullname: Matthys – volume: 3 year: 2015 ident: b0445 article-title: Safety data of Montanide ISA 51 VG and Montanide ISA 720 VG, two adjuvants dedicated to human therapeutic vaccines. publication-title: J ImmunoTher Cancer contributor: fullname: Koziol – volume: 14 start-page: 1412 year: 1996 end-page: 1416 ident: b0080 article-title: In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid publication-title: Vaccine contributor: fullname: Siber – volume: 7 start-page: e41451 year: 2012 ident: b0465 article-title: Matrix-M™ adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen publication-title: PLoS One contributor: fullname: Stertman – volume: 165 start-page: 1228 year: 2000 end-page: 1235 ident: b0295 article-title: CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses publication-title: J Immunol contributor: fullname: Wagner – volume: 8 start-page: 149 year: 2017 ident: b0420 article-title: A comparative phase i study of combination, homologous subtype-C DNA, MVA, and Env gp140 protein/adjuvant HIV vaccines in two immunization regimes publication-title: Front Immunol contributor: fullname: Hayes – volume: 1494 start-page: 15 year: 2017 end-page: 27 ident: b0280 article-title: Development of the CpG adjuvant 1018: a case study publication-title: Methods Mol Biol contributor: fullname: Campbell – volume: 8 start-page: 7 year: 2011 ident: b0520 article-title: GM-CSF and IL-2 as adjuvant enhance the immune effect of protein vaccine against foot-and-mouth disease publication-title: Virol J contributor: fullname: Wang – volume: 35 start-page: 7127 year: 2017 end-page: 7132 ident: b0500 article-title: A phase II randomized study to determine the safety and immunogenicity of the novel PIKA rabies vaccine containing the PIKA adjuvant using an accelerated regimen publication-title: Vaccine contributor: fullname: Wang – volume: 30 start-page: 4341 year: 2012 end-page: 4348 ident: b0210 article-title: The mechanism of action of MF59 – an innately attractive adjuvant formulation publication-title: Vaccine contributor: fullname: Seubert – volume: 8 start-page: 1620 year: 2012 end-page: 1629 ident: b0505 article-title: IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques publication-title: Human Vacc Immunotherapeutics. contributor: fullname: Ganneru – volume: 4 start-page: 249 year: 2004 end-page: 259 ident: b0300 article-title: Immunotherapeutic uses of CpG oligodeoxynucleotides publication-title: Nat Rev Immunol contributor: fullname: Klinman – volume: 34 start-page: 3780 year: 2016 end-page: 3786 ident: b0625 article-title: Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax™ delta inulin adjuvant publication-title: Vaccine contributor: fullname: Barr – volume: 24 start-page: 5937 year: 2006 end-page: 5949 ident: b0335 article-title: Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only publication-title: Vaccine contributor: fullname: Dessy – volume: 11 start-page: e0161730 year: 2016 ident: b0610 article-title: PolyICLC exerts Pro- and anti-HIV effects on the DC-T cell milieu in vitro and in vivo publication-title: PLoS ONE contributor: fullname: Kenney – volume: 16 start-page: 55 year: 2017 end-page: 63 ident: b0355 article-title: Adjuvant system AS01: helping to overcome the challenges of modern vaccines publication-title: Expert Rev Vacc contributor: fullname: Garçon – volume: 20 start-page: 709 year: 2002 end-page: 760 ident: b0305 article-title: CpG motifs in bacterial DNA and their immune effects publication-title: Annu Rev Immunol contributor: fullname: Krieg – volume: 6 start-page: 207 year: 2015 ident: b0230 article-title: AS03-adjuvanted, very-low-dose influenza vaccines induce distinctive immune responses compared to unadjuvanted high-dose vaccines in BALB/c Mice publication-title: Front Immunol contributor: fullname: Beaulieu – volume: 88 start-page: 202 year: 1996 ident: b0525 article-title: Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines publication-title: Blood contributor: fullname: Huseby – ident: 10.1016/j.vaccine.2019.04.055_b0015 – volume: 208 start-page: 1295 year: 1965 ident: 10.1016/j.vaccine.2019.04.055_b0385 article-title: Cation permeability of phospholipid model membranes: effect of narcotics publication-title: Nature doi: 10.1038/2081295a0 contributor: fullname: Bangham – volume: 76 start-page: 229 year: 2008 ident: 10.1016/j.vaccine.2019.04.055_b0365 article-title: Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS, S/AS01B vaccine in rhesus primates publication-title: Infect Immun doi: 10.1128/IAI.00977-07 contributor: fullname: Pichyangkul – volume: 32 start-page: 6377 year: 2014 ident: 10.1016/j.vaccine.2019.04.055_b0265 article-title: Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer publication-title: Vaccine doi: 10.1016/j.vaccine.2014.06.065 contributor: fullname: Scheiermann – volume: 22 start-page: 19 year: 2011 ident: 10.1016/j.vaccine.2019.04.055_b0535 article-title: Role of IL-15 in immune-mediated and infectious diseases publication-title: Cytokine Growth Factor Rev doi: 10.1016/j.cytogfr.2010.09.003 contributor: fullname: Di Sabatino – volume: 35 start-page: 6218 year: 2017 ident: 10.1016/j.vaccine.2019.04.055_b0415 article-title: Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: a phase 1a/1b, randomized, double-blind multi-centre trial publication-title: Vaccine doi: 10.1016/j.vaccine.2017.09.027 contributor: fullname: Sirima – volume: 11 start-page: 349 year: 2012 ident: 10.1016/j.vaccine.2019.04.055_b0240 article-title: Development and evaluation of AS03, an adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion publication-title: Expert Rev Vacc doi: 10.1586/erv.11.192 contributor: fullname: Garçon – volume: 51 start-page: 207 year: 1984 ident: 10.1016/j.vaccine.2019.04.055_b0165 article-title: The role of complement in the induction and regulation of immune responses publication-title: Immunology contributor: fullname: Egwang – volume: 34 start-page: 3780 year: 2016 ident: 10.1016/j.vaccine.2019.04.055_b0625 article-title: Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax™ delta inulin adjuvant publication-title: Vaccine doi: 10.1016/j.vaccine.2016.05.071 contributor: fullname: Gordon – volume: 25 start-page: 4575 year: 2007 ident: 10.1016/j.vaccine.2019.04.055_b0115 article-title: Activation of dendritic cells and induction of CD4+ T cell differentiation by aluminum-containing adjuvants publication-title: Vaccine doi: 10.1016/j.vaccine.2007.03.045 contributor: fullname: Sokolovska – volume: 35 start-page: 7127 year: 2017 ident: 10.1016/j.vaccine.2019.04.055_b0500 article-title: A phase II randomized study to determine the safety and immunogenicity of the novel PIKA rabies vaccine containing the PIKA adjuvant using an accelerated regimen publication-title: Vaccine doi: 10.1016/j.vaccine.2017.10.097 contributor: fullname: Kalimuddin – volume: 3 start-page: 139 year: 2014 ident: 10.1016/j.vaccine.2019.04.055_b0050 article-title: Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice publication-title: Human Vacc doi: 10.4161/hv.3.4.4309 contributor: fullname: Caulfield – volume: 156 start-page: 431 year: 1977 ident: 10.1016/j.vaccine.2019.04.055_b0095 article-title: Eosinophil response to alum adjuvants: involvement of t cells in non-antigen-dependent mechanisms publication-title: Proce Soc Experimental Biol Med doi: 10.3181/00379727-156-39951 contributor: fullname: Walls – volume: 19 start-page: 3836 year: 2001 ident: 10.1016/j.vaccine.2019.04.055_b0430 article-title: Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma publication-title: J Clin Oncol doi: 10.1200/JCO.2001.19.18.3836 contributor: fullname: Lee – volume: 7 start-page: 10834 year: 2013 ident: 10.1016/j.vaccine.2019.04.055_b0045 article-title: Engineering an effective immune adjuvant by designed control of shape and crystallinity of aluminum oxyhydroxide nanoparticles publication-title: ACS Nano doi: 10.1021/nn404211j contributor: fullname: Sun – volume: 32 start-page: 155 year: 1998 ident: 10.1016/j.vaccine.2019.04.055_b0025 article-title: Aluminum compounds as vaccine adjuvants publication-title: Adv Drug Deliv Rev doi: 10.1016/S0169-409X(98)00008-8 contributor: fullname: Gupta – ident: 10.1016/j.vaccine.2019.04.055_b0100 doi: 10.1016/S0264-410X(02)00169-X – volume: 29 start-page: 2461 year: 2011 ident: 10.1016/j.vaccine.2019.04.055_b0245 article-title: Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity publication-title: Vaccine doi: 10.1016/j.vaccine.2011.01.011 contributor: fullname: Morel – ident: 10.1016/j.vaccine.2019.04.055_b0010 – volume: 17 start-page: 479 year: 2011 ident: 10.1016/j.vaccine.2019.04.055_b0155 article-title: Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity publication-title: Nat Med doi: 10.1038/nm.2306 contributor: fullname: Flach – ident: 10.1016/j.vaccine.2019.04.055_b0595 – volume: 1 start-page: 111 year: 2002 ident: 10.1016/j.vaccine.2019.04.055_b0425 article-title: Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines publication-title: Expert Rev Vacc doi: 10.1586/14760584.1.1.111 contributor: fullname: Aucouturier – volume: 16 start-page: 55 year: 2017 ident: 10.1016/j.vaccine.2019.04.055_b0355 article-title: Adjuvant system AS01: helping to overcome the challenges of modern vaccines publication-title: Expert Rev Vacc doi: 10.1080/14760584.2016.1213632 contributor: fullname: Didierlaurent – volume: 12 start-page: e0185843 year: 2017 ident: 10.1016/j.vaccine.2019.04.055_b0215 article-title: Vaccine adjuvant MF59 promotes the intranodal differentiation of antigen-loaded and activated monocyte-derived dendritic cells publication-title: PLoS ONE doi: 10.1371/journal.pone.0185843 contributor: fullname: Cioncada – volume: 26 start-page: 1375 year: 2008 ident: 10.1016/j.vaccine.2019.04.055_b0370 article-title: Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers publication-title: Vaccine doi: 10.1016/j.vaccine.2007.12.038 contributor: fullname: Vandepapelière – volume: 36 start-page: 5226 year: 2018 ident: 10.1016/j.vaccine.2019.04.055_b0565 article-title: Polysaccharides as vaccine adjuvants publication-title: Vaccine doi: 10.1016/j.vaccine.2018.07.040 contributor: fullname: Sun – volume: 10 start-page: 437 year: 2011 ident: 10.1016/j.vaccine.2019.04.055_b0575 article-title: Influenza virosomes as a vaccine adjuvant and carrier system publication-title: Expert Rev Vacc doi: 10.1586/erv.11.15 contributor: fullname: Moser – volume: 12 start-page: 159 year: 2016 ident: 10.1016/j.vaccine.2019.04.055_b0440 article-title: Safety and tolerability evaluation of the use of Montanide ISA™51 as vaccine adjuvant: a systematic review publication-title: Human Vacc Immunotherapeutics doi: 10.1080/21645515.2015.1071455 contributor: fullname: van Doorn – volume: 180 start-page: 5402 year: 2008 ident: 10.1016/j.vaccine.2019.04.055_b0205 article-title: The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells publication-title: J Immunol doi: 10.4049/jimmunol.180.8.5402 contributor: fullname: Seubert – volume: 6 start-page: 207 year: 2015 ident: 10.1016/j.vaccine.2019.04.055_b0230 article-title: AS03-adjuvanted, very-low-dose influenza vaccines induce distinctive immune responses compared to unadjuvanted high-dose vaccines in BALB/c Mice publication-title: Front Immunol doi: 10.3389/fimmu.2015.00207 contributor: fullname: Yam – volume: 3 start-page: e113 year: 2016 ident: 10.1016/j.vaccine.2019.04.055_b0360 article-title: QS-21: a potent vaccine adjuvant publication-title: Natural Products Chem Res contributor: fullname: Zhu – volume: 19 start-page: 455 year: 1999 ident: 10.1016/j.vaccine.2019.04.055_b0530 article-title: Induction of mucosal immune responses by administration of liposome-antigen formulations and interleukin-12 publication-title: J Interferon Cytokine Res doi: 10.1089/107999099313893 contributor: fullname: Baca-Estrada – ident: 10.1016/j.vaccine.2019.04.055_b0255 doi: 10.1038/374546a0 – volume: 6 start-page: 723 year: 2007 ident: 10.1016/j.vaccine.2019.04.055_b0325 article-title: GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives publication-title: Expert Rev Vacc doi: 10.1586/14760584.6.5.723 contributor: fullname: Garçon – volume: 25 start-page: 763 year: 2007 ident: 10.1016/j.vaccine.2019.04.055_b0550 article-title: Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity publication-title: Vaccine doi: 10.1016/j.vaccine.2006.08.013 contributor: fullname: Huleatt – volume: 3 start-page: 406 year: 2012 ident: 10.1016/j.vaccine.2019.04.055_b0040 article-title: Mechanism of immunopotentiation and safety of aluminum adjuvants publication-title: Front Immunol. contributor: fullname: Hogenesch – volume: 8 start-page: 7 year: 2011 ident: 10.1016/j.vaccine.2019.04.055_b0520 article-title: GM-CSF and IL-2 as adjuvant enhance the immune effect of protein vaccine against foot-and-mouth disease publication-title: Virol J doi: 10.1186/1743-422X-8-7 contributor: fullname: Zhang – ident: 10.1016/j.vaccine.2019.04.055_b0225 – volume: 4 start-page: 249 year: 2004 ident: 10.1016/j.vaccine.2019.04.055_b0300 article-title: Immunotherapeutic uses of CpG oligodeoxynucleotides publication-title: Nat Rev Immunol doi: 10.1038/nri1329 contributor: fullname: Klinman – volume: 7 start-page: e29231 year: 2012 ident: 10.1016/j.vaccine.2019.04.055_b0510 article-title: Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine with or without IL-12 and/or IL-15 Plasmid Cytokine Adjuvant in Healthy, HIV-1 Uninfected Adults publication-title: PLoS ONE doi: 10.1371/journal.pone.0029231 contributor: fullname: Kalams – volume: 2010 year: 2010 ident: 10.1016/j.vaccine.2019.04.055_b0485 article-title: Immunomodulatory Effects of dsRNA and Its Potential as Vaccine Adjuvant %J publication-title: J Biomed Biotechnol doi: 10.1155/2010/690438 contributor: fullname: Jin – volume: 30 start-page: 4341 year: 2012 ident: 10.1016/j.vaccine.2019.04.055_b0210 article-title: The mechanism of action of MF59 – an innately attractive adjuvant formulation publication-title: Vaccine doi: 10.1016/j.vaccine.2011.09.061 contributor: fullname: O’Hagan – ident: 10.1016/j.vaccine.2019.04.055_b0290 doi: 10.1097/01.aids.0000183514.37513.d2 – volume: 13 start-page: 1263 year: 1995 ident: 10.1016/j.vaccine.2019.04.055_b0375 article-title: Adjuvants for human vaccines—current status, problems and future prospects publication-title: Vaccine doi: 10.1016/0264-410X(95)00011-O contributor: fullname: Gupta – volume: 3 start-page: 3 year: 2018 ident: 10.1016/j.vaccine.2019.04.055_b0410 article-title: Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a Phase 2 clinical trial publication-title: npj Vaccines doi: 10.1038/s41541-017-0043-3 contributor: fullname: Pillet – ident: 10.1016/j.vaccine.2019.04.055_b0135 doi: 10.1002/eji.200838549 – volume: 2 start-page: 189 year: 2003 ident: 10.1016/j.vaccine.2019.04.055_b0570 article-title: Virosomal adjuvanted antigen delivery systems publication-title: Expert Rev Vacc doi: 10.1586/14760584.2.2.189 contributor: fullname: Moser – ident: 10.1016/j.vaccine.2019.04.055_b0630 doi: 10.5582/ddt.2015.01025 – ident: 10.1016/j.vaccine.2019.04.055_b0220 – volume: 210 start-page: 747 year: 1966 ident: 10.1016/j.vaccine.2019.04.055_b0200 article-title: Antigenicity of soluble protein in the presence of high levels of antibody : a possible mode of action of the antigen adjuvants publication-title: Nature doi: 10.1038/210747a0 contributor: fullname: Herbert – ident: 10.1016/j.vaccine.2019.04.055_b0350 – volume: 252 start-page: 252 year: 1974 ident: 10.1016/j.vaccine.2019.04.055_b0380 article-title: Liposomes as immunological adjuvants publication-title: Nature doi: 10.1038/252252a0 contributor: fullname: Allison – volume: 2 start-page: 244 year: 1930 ident: 10.1016/j.vaccine.2019.04.055_b0030 article-title: Insoluble precipitates in diphtheria and tetanus immunization publication-title: Br Med J doi: 10.1136/bmj.2.3632.244 contributor: fullname: Glenny – volume: 9 year: 2018 ident: 10.1016/j.vaccine.2019.04.055_b0645 article-title: Alum/toll-like receptor 7 adjuvant enhances the expansion of memory B cell compartment within the draining lymph node publication-title: Front Immunol doi: 10.3389/fimmu.2018.00641 contributor: fullname: Vo – volume: 3 year: 2015 ident: 10.1016/j.vaccine.2019.04.055_b0445 article-title: Safety data of Montanide ISA 51 VG and Montanide ISA 720 VG, two adjuvants dedicated to human therapeutic vaccines. publication-title: J ImmunoTher Cancer contributor: fullname: Ascarateil – volume: 227 start-page: 44 year: 2008 ident: 10.1016/j.vaccine.2019.04.055_b0475 article-title: Functional evolution of the TICAM-1 pathway for extrinsic RNA sensing publication-title: Immunol Rev doi: 10.1111/j.1600-065X.2008.00723.x contributor: fullname: Seya – ident: 10.1016/j.vaccine.2019.04.055_b0160 – volume: 10 start-page: e0004423 year: 2016 ident: 10.1016/j.vaccine.2019.04.055_b0635 article-title: Phase 1/2a trial of plasmodium vivax malaria vaccine candidate VMP001/AS01B in malaria-naive adults: safety, immunogenicity, and efficacy publication-title: PLoS NeglTrop Dis doi: 10.1371/journal.pntd.0004423 contributor: fullname: Bennett – volume: 20 start-page: 561 year: 1999 ident: 10.1016/j.vaccine.2019.04.055_b0145 article-title: T-cell priming by type-1and type-2 polarized dendritic cells: the concept of a third signal publication-title: Immunol Today doi: 10.1016/S0167-5699(99)01547-9 contributor: fullname: Kaliński – volume: 15 start-page: 1041 year: 2015 ident: 10.1016/j.vaccine.2019.04.055_b0495 article-title: High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(15)00266-2 contributor: fullname: Liebowitz – start-page: 249 year: 2017 ident: 10.1016/j.vaccine.2019.04.055_b0185 article-title: Chapter 13 - MF59: a safe and potent adjuvant forhuman use contributor: fullname: Kommareddy – volume: 458 start-page: 1191 year: 2009 ident: 10.1016/j.vaccine.2019.04.055_b0330 article-title: The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex publication-title: Nature doi: 10.1038/nature07830 contributor: fullname: Park – volume: 24 start-page: 5937 year: 2006 ident: 10.1016/j.vaccine.2019.04.055_b0335 article-title: Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only publication-title: Vaccine doi: 10.1016/j.vaccine.2006.06.005 contributor: fullname: Giannini – volume: 183 start-page: 6186 year: 2009 ident: 10.1016/j.vaccine.2019.04.055_b0345 article-title: AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity publication-title: J Immunol doi: 10.4049/jimmunol.0901474 contributor: fullname: Didierlaurent – volume: 16 start-page: 289 year: 2017 ident: 10.1016/j.vaccine.2019.04.055_b0545 article-title: Calcium phosphate: a substitute for aluminum adjuvants? publication-title: Expert Rev Vacc doi: 10.1080/14760584.2017.1244484 contributor: fullname: Masson – volume: 24 start-page: 3990 year: 2006 ident: 10.1016/j.vaccine.2019.04.055_b0590 article-title: A new intranasal influenza vaccine based on a novel polycationic lipid—ceramide carbamoyl-spermine (CCS): I. Immunogenicity and efficacy studies in mice publication-title: Vaccine doi: 10.1016/j.vaccine.2005.12.017 contributor: fullname: Joseph – volume: 71 start-page: 635 year: 2002 ident: 10.1016/j.vaccine.2019.04.055_b0400 article-title: Lipopolysaccharide endotoxins publication-title: Annu Rev Biochem doi: 10.1146/annurev.biochem.71.110601.135414 contributor: fullname: Raetz – volume: 25 start-page: 7065 year: 2007 ident: 10.1016/j.vaccine.2019.04.055_b0585 article-title: A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses publication-title: Vaccine doi: 10.1016/j.vaccine.2007.07.052 contributor: fullname: Kammer – ident: 10.1016/j.vaccine.2019.04.055_b0615 – volume: 61 start-page: 195 year: 2009 ident: 10.1016/j.vaccine.2019.04.055_b0275 article-title: Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2008.12.008 contributor: fullname: Vollmer – volume: 3 start-page: e2636 year: 2008 ident: 10.1016/j.vaccine.2019.04.055_b0435 article-title: Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51 publication-title: PLoS One doi: 10.1371/journal.pone.0002636 contributor: fullname: Wu – year: 2018 ident: 10.1016/j.vaccine.2019.04.055_b0340 article-title: Correlates of adjuvanticity: A review on adjuvants in licensed vaccines publication-title: Semin Immunol doi: 10.1016/j.smim.2018.05.001 contributor: fullname: Del Giudice – volume: 9 year: 2017 ident: 10.1016/j.vaccine.2019.04.055_b0650 article-title: Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aal2094 contributor: fullname: Liang – volume: 104 start-page: 11020 year: 2007 ident: 10.1016/j.vaccine.2019.04.055_b0560 article-title: A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.0702403104 contributor: fullname: Döring – ident: 10.1016/j.vaccine.2019.04.055_b0020 doi: 10.1080/14760584.2017.1244484 – volume: 165 start-page: 1228 year: 2000 ident: 10.1016/j.vaccine.2019.04.055_b0295 article-title: CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses publication-title: J Immunol doi: 10.4049/jimmunol.165.3.1228 contributor: fullname: Lipford – ident: 10.1016/j.vaccine.2019.04.055_b0005 – volume: 14 start-page: 1412 year: 1996 ident: 10.1016/j.vaccine.2019.04.055_b0080 article-title: In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid publication-title: Vaccine doi: 10.1016/S0264-410X(96)00073-4 contributor: fullname: Gupta – ident: 10.1016/j.vaccine.2019.04.055_b0515 – volume: 7 start-page: 899 year: 2000 ident: 10.1016/j.vaccine.2019.04.055_b0540 article-title: Calcium phosphate nanoparticle adjuvant publication-title: Clin Diagn Lab Immunol doi: 10.1128/CDLI.7.6.899-903.2000 contributor: fullname: He – volume: 147 start-page: 55 year: 2012 ident: 10.1016/j.vaccine.2019.04.055_b0110 article-title: Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro publication-title: Immunol Lett doi: 10.1016/j.imlet.2012.06.002 contributor: fullname: Ghimire – volume: 8 start-page: 1620 year: 2012 ident: 10.1016/j.vaccine.2019.04.055_b0505 article-title: IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques publication-title: Human Vacc Immunotherapeutics. doi: 10.4161/hv.21407 contributor: fullname: Jalah – volume: 47 start-page: 4954 year: 2018 ident: 10.1016/j.vaccine.2019.04.055_b0070 article-title: Tailoring inorganic nanoadjuvants towards next-generation vaccines publication-title: Chem Soc Rev doi: 10.1039/C8CS00028J contributor: fullname: Li – volume: 61 start-page: 143 year: 1985 ident: 10.1016/j.vaccine.2019.04.055_b0105 article-title: Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation publication-title: Clin Exp Immunol contributor: fullname: Mannhalter – ident: 10.1016/j.vaccine.2019.04.055_b0125 doi: 10.1038/nature06939 – volume: 1494 start-page: 15 year: 2017 ident: 10.1016/j.vaccine.2019.04.055_b0280 article-title: Development of the CpG adjuvant 1018: a case study publication-title: Methods Mol Biol doi: 10.1007/978-1-4939-6445-1_2 contributor: fullname: Campbell – volume: 4 start-page: 5496 year: 2016 ident: 10.1016/j.vaccine.2019.04.055_b0035 article-title: Nanomaterial-based vaccine adjuvants publication-title: J Mater Chem B doi: 10.1039/C6TB01131D contributor: fullname: Sun – volume: 8 start-page: 339 year: 1986 ident: 10.1016/j.vaccine.2019.04.055_b0180 article-title: Immunobiological activities of nontoxic lipid A: enhancement of nonspecific resistance in combination with trehalose dimycolate against viral infection and adjuvant effects publication-title: Int J Immunopharmacol doi: 10.1016/0192-0561(86)90116-5 contributor: fullname: Noel Masihi – volume: 3 year: 2018 ident: 10.1016/j.vaccine.2019.04.055_b0060 article-title: Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want publication-title: NPJ Vaccines doi: 10.1038/s41541-018-0089-x contributor: fullname: HogenEsch – volume: 32 start-page: 5149 year: 2014 ident: 10.1016/j.vaccine.2019.04.055_b0150 article-title: A role for impaired regulatory T cell function in adverse responses to aluminum adjuvant-containing vaccines in genetically susceptible individuals publication-title: Vaccine doi: 10.1016/j.vaccine.2014.07.052 contributor: fullname: Terhune – volume: 10 start-page: s32 year: 2002 ident: 10.1016/j.vaccine.2019.04.055_b0390 article-title: Taking toll: lipid A mimetics as adjuvants and immunomodulators publication-title: Trends Microbiol doi: 10.1016/S0966-842X(02)02426-5 contributor: fullname: Persing – volume: 92 start-page: 703 year: 2001 ident: 10.1016/j.vaccine.2019.04.055_b0450 article-title: Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients publication-title: Int J Cancer doi: 10.1002/1097-0215(20010601)92:5<703::AID-IJC1250>3.0.CO;2-5 contributor: fullname: Yamshchikov – volume: 106 start-page: 3877 year: 2009 ident: 10.1016/j.vaccine.2019.04.055_b0195 article-title: H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.0813390106 contributor: fullname: Galli – volume: 6 year: 2015 ident: 10.1016/j.vaccine.2019.04.055_b0655 article-title: Analysis of immunoglobulin transcripts and hypermutation following SHIVAD8 infection and protein-plus-adjuvant immunization publication-title: Nature Commun doi: 10.1038/ncomms7565 contributor: fullname: Francica – start-page: 211 year: 2000 ident: 10.1016/j.vaccine.2019.04.055_b0190 article-title: The adjuvant MF59: A 10-Year perspective Gary Ott, Ramachandran Radhakrishnan contributor: fullname: Fang – volume: 6 start-page: 685 year: 2007 ident: 10.1016/j.vaccine.2019.04.055_b0140 article-title: Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation publication-title: Expert Rev Vacc doi: 10.1586/14760584.6.5.685 contributor: fullname: Hem – volume: 204 start-page: 1541 year: 2011 ident: 10.1016/j.vaccine.2019.04.055_b0605 article-title: Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects publication-title: J Infect Dis doi: 10.1093/infdis/jir615 contributor: fullname: Baden – volume: 26 start-page: 1272 year: 2012 ident: 10.1016/j.vaccine.2019.04.055_b0085 article-title: Antigen depot is not required for alum adjuvanticity publication-title: FASEB J doi: 10.1096/fj.11-184556 contributor: fullname: Hutchison – volume: 9 start-page: e88979 year: 2014 ident: 10.1016/j.vaccine.2019.04.055_b0405 article-title: GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza publication-title: PLoS ONE doi: 10.1371/journal.pone.0088979 contributor: fullname: Clegg – volume: 32 start-page: 6683 year: 2014 ident: 10.1016/j.vaccine.2019.04.055_b0470 article-title: Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS, S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults publication-title: Vaccine doi: 10.1016/j.vaccine.2014.06.033 contributor: fullname: Kester – volume: 9 start-page: 21697 year: 2017 ident: 10.1016/j.vaccine.2019.04.055_b0130 article-title: Enhanced immune adjuvant activity of aluminum oxyhydroxide nanorods through cationic surface functionalization publication-title: ACS Appl Mater Interfaces doi: 10.1021/acsami.7b05817 contributor: fullname: Sun – volume: 8 start-page: 149 year: 2017 ident: 10.1016/j.vaccine.2019.04.055_b0420 article-title: A comparative phase i study of combination, homologous subtype-C DNA, MVA, and Env gp140 protein/adjuvant HIV vaccines in two immunization regimes publication-title: Front Immunol doi: 10.3389/fimmu.2017.00149 contributor: fullname: Joseph – volume: 70 start-page: 849 year: 2001 ident: 10.1016/j.vaccine.2019.04.055_b0170 article-title: Modes of action of Freund’s adjuvants in experimental models of autoimmune diseases publication-title: J Leukoc Biol doi: 10.1189/jlb.70.6.849 contributor: fullname: Billiau – volume: 30 start-page: 556 year: 2009 ident: 10.1016/j.vaccine.2019.04.055_b0490 article-title: The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA publication-title: Immunity doi: 10.1016/j.immuni.2009.02.005 contributor: fullname: Allen – volume: 7 start-page: e41451 year: 2012 ident: 10.1016/j.vaccine.2019.04.055_b0465 article-title: Matrix-M™ adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen publication-title: PLoS One doi: 10.1371/journal.pone.0041451 contributor: fullname: Reimer – ident: 10.1016/j.vaccine.2019.04.055_b0260 – volume: 27 start-page: 1787 year: 2009 ident: 10.1016/j.vaccine.2019.04.055_b0455 article-title: Advances in saponin-based adjuvants publication-title: Vaccine. doi: 10.1016/j.vaccine.2009.01.091 contributor: fullname: Sun – ident: 10.1016/j.vaccine.2019.04.055_b0175 doi: 10.1586/erv.12.140 – volume: 9 start-page: 1478 year: 2007 ident: 10.1016/j.vaccine.2019.04.055_b0315 article-title: Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax publication-title: Microbes Infect doi: 10.1016/j.micinf.2007.08.002 contributor: fullname: Klinman – volume: 30 start-page: 287 year: 2009 ident: 10.1016/j.vaccine.2019.04.055_b0065 article-title: Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants publication-title: Trends Pharmacol Sci doi: 10.1016/j.tips.2009.03.005 contributor: fullname: Aimanianda – volume: 6 start-page: e22273 year: 2011 ident: 10.1016/j.vaccine.2019.04.055_b0580 article-title: Virosome-formulated plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children publication-title: PLoS One doi: 10.1371/journal.pone.0022273 contributor: fullname: Cech – volume: 18 start-page: 2188 year: 2000 ident: 10.1016/j.vaccine.2019.04.055_b0090 article-title: Stability of aluminium-containing adjuvants during aging at room temperature publication-title: Vaccine doi: 10.1016/S0264-410X(00)00031-1 contributor: fullname: Burrell – volume: 88 start-page: 202 year: 1996 ident: 10.1016/j.vaccine.2019.04.055_b0525 article-title: Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines publication-title: Blood doi: 10.1182/blood.V88.1.202.202 contributor: fullname: Disis – ident: 10.1016/j.vaccine.2019.04.055_b0320 – volume: 33 start-page: 7518 year: 2015 ident: 10.1016/j.vaccine.2019.04.055_b0235 article-title: Particle-based platforms for malaria vaccines publication-title: Vaccine doi: 10.1016/j.vaccine.2015.09.097 contributor: fullname: Wu – volume: 9 start-page: 1595 year: 2013 ident: 10.1016/j.vaccine.2019.04.055_b0120 article-title: NLRP3 inflammasome activation induced by engineered nanomaterials publication-title: Small doi: 10.1002/smll.201201962 contributor: fullname: Sun – volume: 4 start-page: 114 year: 2013 ident: 10.1016/j.vaccine.2019.04.055_b0075 article-title: Mechanisms of action of adjuvants publication-title: Front Immunol doi: 10.3389/fimmu.2013.00114 contributor: fullname: Awate – volume: 420 start-page: 1 year: 2009 ident: 10.1016/j.vaccine.2019.04.055_b0480 article-title: Pathogen recognition in the innate immune response publication-title: Biochem J doi: 10.1042/BJ20090272 contributor: fullname: Kumar – ident: 10.1016/j.vaccine.2019.04.055_b0310 doi: 10.1002/1521-4141(200012)30:12<3591::AID-IMMU3591>3.0.CO;2-J – volume: 33 start-page: 492 year: 2010 ident: 10.1016/j.vaccine.2019.04.055_b0555 article-title: Vaccine adjuvants: putting innate immunity to work publication-title: Immunity doi: 10.1016/j.immuni.2010.10.002 contributor: fullname: Coffman – volume: 12 start-page: 472 year: 1994 ident: 10.1016/j.vaccine.2019.04.055_b0055 article-title: Effect of protein adsorption on the surface charge characteristics of aluminium-containing adjuvants publication-title: Vaccine doi: 10.1016/0264-410X(94)90127-9 contributor: fullname: Al-Shakhshir – volume: 2016 start-page: 163 issue: 71 year: 1999 ident: 10.1016/j.vaccine.2019.04.055_b0600 article-title: The safety and immunogenicity of an interleukin-12-enhanced multiantigen DNA vaccine delivered by electroporation for the treatment of HIV-1 infection publication-title: J Acquir Immune Defic Syndr contributor: fullname: Jacobson – volume: 32 start-page: 766 year: 2001 ident: 10.1016/j.vaccine.2019.04.055_b0620 article-title: Use of cytokines in human immunodeficiency virus-infected patients: colony-stimulating factors, erythropoietin, and interleukin-2 publication-title: Clin Infect Dis doi: 10.1086/319227 contributor: fullname: Mayer – volume: 42 start-page: 4640 year: 1999 ident: 10.1016/j.vaccine.2019.04.055_b0395 article-title: 3-O-Desacyl monophosphoryl lipid A derivatives: synthesis and immunostimulant activities publication-title: J Med Chem doi: 10.1021/jm990222b contributor: fullname: Johnson – volume: 9 start-page: 425 year: 2010 ident: 10.1016/j.vaccine.2019.04.055_b0460 article-title: Saponins as cytotoxic agents: a review publication-title: Phytochem Rev doi: 10.1007/s11101-010-9183-z contributor: fullname: Podolak – volume: 31 start-page: 443 year: 2011 ident: 10.1016/j.vaccine.2019.04.055_b0250 article-title: H5N1 influenza vaccine formulated with AS03A induces strong cross-reactive and polyfunctional CD4 T-cell responses publication-title: J Clin Immunol doi: 10.1007/s10875-010-9490-6 contributor: fullname: Moris – volume: 10 start-page: 499 year: 2011 ident: 10.1016/j.vaccine.2019.04.055_b0270 article-title: CpG DNA as a vaccine adjuvant publication-title: Expert Rev Vacc doi: 10.1586/erv.10.174 contributor: fullname: Bode – volume: 16 start-page: 413 year: 2009 ident: 10.1016/j.vaccine.2019.04.055_b0640 article-title: Virosomal hepatitis A vaccine: comparing intradermal and subcutaneous with intramuscular administration publication-title: J Travel Med doi: 10.1111/j.1708-8305.2009.00351.x contributor: fullname: Frösner – volume: 11 start-page: e0161730 year: 2016 ident: 10.1016/j.vaccine.2019.04.055_b0610 article-title: PolyICLC exerts Pro- and anti-HIV effects on the DC-T cell milieu in vitro and in vivo publication-title: PLoS ONE doi: 10.1371/journal.pone.0161730 contributor: fullname: Aravantinou – volume: 7 start-page: e46094 year: 2012 ident: 10.1016/j.vaccine.2019.04.055_b0285 article-title: Phase 1 study in malaria naïve adults of BSAM2/alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum Malaria publication-title: PLOS One doi: 10.1371/journal.pone.0046094 contributor: fullname: Ellis – volume: 20 start-page: 709 year: 2002 ident: 10.1016/j.vaccine.2019.04.055_b0305 article-title: CpG motifs in bacterial DNA and their immune effects publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.20.100301.064842 contributor: fullname: Krieg |
| SSID | ssj0005319 |
| Score | 2.6883168 |
| SecondaryResourceType | review_article |
| Snippet | In conjugate, inactivated, recombinant, and toxoid vaccines, adjuvants are extensively and essentially used for enhanced and long-lasting protective immune... |
| SourceID | proquest crossref pubmed elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 3167 |
| SubjectTerms | Adaptive immunity Adjuvant Adjuvanticity Adjuvants Aluminum Aluminum salt Antigens CpG islands Diphtheria FDA approval Formulations Hepatitis Human papillomavirus Immune response Immune system Immunogenicity Infectious diseases Influenza Licenses Lipids Malaria Molecular modelling Oligonucleotides Structure-activity relationship Structure-activity relationships Tetanus Tropical diseases Vaccines Viruses Whooping cough |
| SummonAdditionalLinks | – databaseName: ScienceDirect Freedom Collection 2013 dbid: .~1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dS-NAEB9EUHwRrV9V79gD8cm02WSTbHw75KQcVASt9G3Z7G6gBVOxrdAX_3Zn8tFWUA7uMclMWHZm54OZ3yzARRjrOEgF96RIYw89nu9J7aQnuZY8R5uZOKro9u_i3kD8HUbDDbhpsDDUVlnb_sqml9a6ftOtd7P7Mhp1H_zSl_tDDEGoXEWAX4EahjrdeV9r8wjLyz2I2CPqFYqnO-68aUPla-rwSsuJp4T4-9o_fRd_ln7odg926wCS_a7WuA8brmjBVnWl5KIF2_26WN6Cy_tqLPXiij2uUFbTK3bJ7lcDq5Gn9UQ9MSUwlzXsB9B_qpbNtB3P36hd5poN1qEwDGNHVs2fnb8iWWHZsyMg8Wj6zCb5kg__N1scwuD2z-NNz6svX_BMmIYzz8lcRIHjPOEuckJmIY1q1w7dF89knvo2tZHhuW-tzlKLeVfic51mucmMdi4Ij2CzmBTuBFgYJYLScIOWV5g8zixaNm6DyGjtIiPa0Gm2XL1UMzZU03w2VrWMFMlI-UKhjNogG8GoT8qi0A_8i_W8EaSqT-tUBZT0YqIYJG34tfyM54yKJ7pwk3lJg7FwJDhvw3GlAMvFhjTvIk746f-v6wx26In6EoLkHDZReO4Hhjuz7Gepzx8zif09 priority: 102 providerName: Elsevier |
| Title | Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity |
| URI | https://dx.doi.org/10.1016/j.vaccine.2019.04.055 https://www.ncbi.nlm.nih.gov/pubmed/31047671 https://www.proquest.com/docview/2222595627 https://search.proquest.com/docview/2229235411 |
| Volume | 37 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhR1da9sw8FhbNvYyuuwrW1s0GH2qU8uWLXkvpS0t2UZCGE3Jm5AlGRao0y1JIS_77bvzR7yHfbzYBuuE0J3uQ_cF8CFOTRplggdKZGmAEi8MlPEqUNwoXiDPlJ48uqNxOpyKz7Nk1ly4LZuwypYnVozaLSzdkZ9GZJigMh_Js_vvAXWNIu9q00JjB_Z4FKZE1XImuxCPuGrsgWaGCAQPZ10Gz-l88GAsua4puiurqp1Stt-fZdPfdM9KBl3vw7NGeWTnNbafwyNf9uBx3U5y04Mno8ZR3oPjSV2SenPCbroMq-UJO2aTrlg1wvRuKR6mSsplLfgLGN3Wy2bGzdcPFCrzkU1_T4NhqDeyuvbs-gcOKx2785RE_G15xxbFFg7nW21ewvT66uZyGDSNFwIbZ_Eq8KoQSeQ5l9wnXqg8pjLtxqPo4rkqstBlLrG8CJ0zeebQ5pIhN1le2Nwa76P4FeyWi9K_ARYnUpAJbpHrClukuUOuxl2UWGN8YkUfBu2W6_u6voZuA8_musGRJhzpUGjEUR9UixjdKAm18NcoA_4HetAiUjcndak7uurD--1vPGPkODGlX6yrMagHJ4LzPryuCWC72JhqXaSSv_335O_gKa2E4g4ieQC7iCB_iOrMKj-CncFPflRRLj7VJX7vnX_6Mhzj--JqPPn6C-zw9_8 |
| link.rule.ids | 315,783,787,4510,12069,12236,21401,24129,27937,27938,31732,31733,33279,33280,33757,33758,43323,43592,43818,45598,45692,74080,74349,74637 |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3db9MwED_BELAXBIWxwgAjoT0tW5w4ic3LNE1MBdZpD-3UN8uxHYlKS8faTup_v7vEaffAx3N8lpU734fvd3cAX9Lc5IkSPJJC5RFavDiSxstIciN5hTqz8JTRHV7kg7H4Mckm4cFtHmCVnU5sFLWbWXojP0ooMEFnPimOb35HNDWKsqthhMZjeIJmX9EEA3n6AOKRNoM9MMwQkeDxZFPBczQ9vDOWUteE7lJNt1Oq9vuzbfqb79nYoLOX8CI4j-yk5fYreOTrHjxtx0muevBsGBLlPdi_bFtSrw7YaFNhNT9g--xy06waaXpXhIdpinJZR_4ahlftsZlx0-UdQWW-svHDMhiGfiNre88ub3FZ7di1pyLiX_NrNqvWdLjfYvUGxmffRqeDKAxeiGyq0kXkZSWyxHNecJ95IcuU2rQbj6aLl7JSsVMus7yKnTOlchhzFTE3qqxsaY33SboDW_Ws9rvA0qwQFIJb1LrCVnnpUKtxl2TWGJ9Z0YfD7pfrm7a_hu6AZ1MdeKSJRzoWGnnUB9kxRgcnoTX-Gm3A_0j3OkbqcFPneiNXffi8_ox3jBInpvazZbMG_eBMcN6Ht60ArA-bUq-LvODv_r35J3g-GA3P9fn3i5_vYZtORRiEpNiDLWSW_4CuzaL82MjvPWQk9cc |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9swDCa2Dit2KbZs69K1mwYMPVWtZcu2vMtQdAu6R4ocmiI3QZZkYAHqdE1SIP--pC0nPexxtiUIJkV-ND-SAB-TzGRxIQVXssg4eryIK-MVV8IoUaHNzD1ldIcX2flYfp-kk8B_mgdaZWcTG0PtZpb-kZ_EFJggmMdQvQq0iNGXweeb35wmSFGmNYzTeAxP0CtK0nB19oDukTRDPjDkkFyKaLKp5jmZHt8ZS2lsYnoVTedTqvz7s5_6Gw5t_NHgOewEIMlOW8m_gEe-7sHTdrTkqgfbw5A078HhqG1PvTpil5tqq_kRO2SjTeNqXNO7Im5MU6DLuuUvYXjVHpsZN13eEW3mExs_LIlhiCFZ24d2eYuv1Y5deyoo_jW_ZrNqvQ73W6xewXjw9fLsnIchDNwmRbLgXlUyjb0QufCpl6pMqGW78ejGRKmqInKFS62oIudMWTiMv_JImKKsbGmN93HyGrbqWe3fAEvSXFI4btECS1tlpUMLJ1ycWmN8amUfjrtPrm_aXhu6I6FNdZCRJhnpSGqUUR9UJxgdAEMLBDT6g_8t3e8EqcOtneuNjvXhw_ox3jdKopjaz5bNO4iJUylEH3ZbBVgfNqG-F1ku9v69-XvYRtXVP79d_HgLz-hQREeI833YQln5A0Q5i_Jdo7735iH5_A |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Vaccine+adjuvants%3A+Understanding+the+structure+and+mechanism+of+adjuvanticity&rft.jtitle=Vaccine&rft.au=Shi%2C+Shuting&rft.au=Zhu%2C+Haoru&rft.au=Xia%2C+Xinyu&rft.au=Liang%2C+Zhihui&rft.date=2019-05-27&rft.pub=Elsevier+Limited&rft.issn=0264-410X&rft.eissn=1873-2518&rft.volume=37&rft.issue=24&rft.spage=3167&rft_id=info:doi/10.1016%2Fj.vaccine.2019.04.055&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0264-410X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0264-410X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0264-410X&client=summon |